Citrine Global (CTGL) 10-K 8 Apr 22 2021 FY Annual report Financial data

Cover

Cover - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Apr. 08, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-55680
Entity Registrant Name	CITRINE GLOBAL, CORP.
Entity Central Index Key	0001498067
Entity Tax Identification Number	68-0080601
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2 4 Haogen Street
Entity Address, City or Town	Herzelia
Entity Address, Country	IL
Entity Address, Postal Zip Code	5250501
City Area Code	972
Local Phone Number	98851422
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 6,752
Entity Common Stock, Shares Outstanding		942,568,006
ICFR Auditor Attestation Flag	false
Auditor Name	Somekh Chaikin
Auditor Location	Tel Aviv, Israel
Auditor Firm ID	1057

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 270	$ 206
Restricted cash	10
Prepaid share based payment to a service provider (Note 6)		1,737
Trading securities (Note 8)		522
Short-term loan measured at fair value (Note 8)		165
Short-term loan (Note 9I)	15
Prepaid expenses	30	10
Other current assets	24	9
T o t a l Current assets	349	2,649
Non-current assets
Investments valued under the measurement alternative (Note 3)	450	450
Property and equipment, net (Note 4)	256	6
Total non-current assets	706	456
T o t a l assets	1,055	3,105
Current Liabilities
Accounts payable and accrued expenses	226	172
Accrued compensation	838	304
Fair value of a liability in connection with stock exchange agreement (Note 8)		72
Convertible component in convertible notes (Note 5)		381
Convertible notes (Note 5)		773
T o t a l current liabilities	1,064	1,702
Non-current liability
Convertible notes (Note 5)	1,431
T o t a l liabilities	2,495	1,702
Stockholders’ Equity (Deficit) (Note 6)
Common stock, par value $0.0001 per share, 1,500,000,000 shares authorized at December 31, 2021 and December 31, 2020; 942,568,006 shares issued and outstanding at December 31, 2021 and December 31, 2020	94	94
Additional paid-in capital	22,073	20,414
Stock to be issued	44	30
Accumulated deficit	(23,757)	(19,241)
Accumulated other comprehensive income	106	106
T o t a l stockholders’ equity (deficit)	(1,440)	1,403
T o t a l liabilities and stockholders’ equity (deficit)	$ 1,055	$ 3,105

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	1,500,000,000	1,500,000,000
Common Stock, shares issued	942,568,006	942,568,006
Common Stock, shares outstanding	942,568,006	942,568,006

Consolidated Statements of Oper

Consolidated Statements of Operation and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021		Dec. 31, 2020
Income Statement [Abstract]
Revenues			$ 12
Cost of revenues			(14)
Gross loss			(2)
Research and development expenses	(96)		(17)
Marketing, general and administrative expenses	(3,239)		(8,350)
Gain from deconsolidation of a subsidiary (Note 1)			52
Operating loss	(3,335)		(8,317)
Financing expenses, net:
Fair value adjustment of liability in connection with stock exchange agreement (Note 8)			(72)
Change in fair value of trading securities (Note 8)			7
Change in fair value of short-term loan measured at fair value (Note 8)			20
Change in fair value of convertible component in convertible notes (Note 5)	(176)		(287)
Expenses related to convertible loan terms	(333)
Loss from extinguishment in connection with convertible loan restructuring (Note 5)	(620)
Other financing expenses, net	(52)		10
Financing expenses, net	(1,181)		(322)
Net loss attributable to Common stockholders	$ (4,516)		$ (8,639)
Loss per Common Stock (basic and diluted)	$ 0	[1]	$ (0.02)
Basic weighted average number of shares of Common Stock outstanding	942,568,006		476,622,892
Comprehensive loss:
Net loss	$ (4,516)		$ (8,639)
Other comprehensive loss attributable to foreign currency translation			(10)
Comprehensive loss	$ (4,516)		$ (8,649)
[1]	Less than $0.01

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]Redeemable Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock to be Issued [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 300	$ 4	$ 10,042	$ 30	$ (10,602)	$ 116	$ (410)
Beginning Balance, shares at Dec. 31, 2019	10,344,828	35,449,400
Conversion Preferred Stock to Common Stock	$ (300)	$ 1	299				300
Conversion Preferred Stock to Common Stock, shares	(10,344,828)	10,344,828
Issuance of Common Stock		$ 86	91				177
Issuance of Common Stock, shares		864,997,122
Issuance of Common Stock to service provider		$ 3	9,155				9,158
Issuance of Common Stock to Service Provider, shares		29,633,186
Waiver of fee by related party			11				11
Warrants issued in connection with convertible notes			302				302
Issuance of Common Stock in exchange investment in marketable securities			514				514
Issuance of Common Stock in exchange investment in marketable securities, shares		2,143,470
Other comprehensive loss						(10)	(10)
Net loss for the period					(8,639)		(8,639)
Ending balance, value at Dec. 31, 2020		$ 94	20,414	30	(19,241)	106	1,403
Ending Balance, shares at Dec. 31, 2020		942,568,006
Modification of warrants in connection with convertible loan restructuring (Note 5)			361				361
Warrants issued in connection with convertible notes			172				172
Classification of embedded conversion feature from liability to equity (Note 5)			670				670
Commitment for issuance of fixed number of ordinary shares				14			14
Share based compensation			456				456
Net loss for the period					(4,516)		(4,516)
Ending balance, value at Dec. 31, 2021		$ 94	$ 22,073	$ 44	$ (23,757)	$ 106	$ (1,440)
Ending Balance, shares at Dec. 31, 2021		942,568,006

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,516)	$ (8,639)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2	7
Finance expenses, net	(20)	2
Change in fair value of convertible component in convertible notes	176	287
Expenses related to convertible loan terms	333
Interest and change in fair value of short-term loan measured at fair value	1	(20)
Inventory subject to refund		1
Loss from extinguishment in connection with convertible loan restructuring (Note 5)	620
Share-based compensation	456
Change in fair value of marketable securities	133	(7)
Gain from deconsolidation of a subsidiary (Note 1)		(52)
Share based payment to a service provider		7,422
Fair value adjustment of liability in connection with stock exchange agreement (Note 8)	(58)	72
Management fee waiver by a related party		11
Changes in operating assets and liabilities:
Accounts receivable		(6)
Prepaid share based payment to a service provider	1,737
Net changes in operating leases		(1)
Related parties		(11)
Prepaid expenses and other current assets	(35)	(22)
Inventory		7
Accounts payable and accrued expenses	589	258
Deferred revenue		(5)
Net cash used in operating activities	(582)	(696)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(252)	(6)
Net cash outflow from deconsolidation of a subsidiary (Appendix A)		(14)
Investment valued under the measurement alternative (Note 3)		(450)
Grant of short-term loan (Note 8)	(15)	(145)
Proceeds from sale of trading securities (Note 8A)	389
Proceeds from repayments of short-term loan	164
Net cash provided by (used in) investing activities	286	(615)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from related parties’ loans		154
Proceeds from issuance of Common Stock		177
Proceeds from the issuance of convertible notes and warrants	350	1,170
Net cash provided by financing activities	350	1,501
Effect of exchange rates on cash and cash equivalents	20	(2)
Net increase in cash and cash equivalents and restricted cash	74	188
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE YEAR	206	18
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR	280	206
Non-cash transactions:
Conversion Preferred Stock to Common Stock		300
Exchange of common stock for investment in trade securities		514
Classification of embedded conversion feature from liability to equity (see note 5)	670
Commitment for issuance of fixed number of ordinary shares	14
Appendix A – Net cash outflow from deconsolidation of a subsidiary
Working capital (excluding cash and cash equivalents), net		(217)
Long term assets		156
Long term liabilities		(5)
Gain from deconsolidation of a subsidiary		$ 52

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
GENERAL	NOTE 1 – GENERAL Citrine Global, Corp. (“Citrine Global” or the “Company”) was incorporated under the laws of the State of Delaware on May 26, 2010. The Company’s common stock is traded in the United States on the OTCQB market under the ticker symbol “CTGL.” Stock Purchase Agreement On January 6, 2020, the Company’s predecessor company, TechCare Corp., a Delaware corporation (“TechCare”), and Citrine S A L Investment & Holdings Ltd., an Israeli corporation and a major shareholder of the Company (“Citrine S A L”), and a group of related persons and entities (the “Citrine S A L Group”) entered into a Common Stock Purchase Agreement (the “Citrine S A L Group Agreement”), which was later amended and restated on February 23, 2020 (the “AR Citrine S A L Group Agreement”). Pursuant to the AR Citrine S A L Group Agreement, TechCare agreed to sell Citrine S A L Group and its group of business partners, up to an aggregate of 893,699,276 shares of TechCare’s common stock, representing approximately 95 % of TechCare’s fully diluted capital, in two tranches, with the initial tranche of up to 452,063,196 shares of the TechCare’s common stock to be sold conditioned upon (i) the resignation of the Company’s existing members of its board of directors (the “Board”), consisting of Oren Traistman and Yossef De-Levy, (ii) the appointment of each of Ora Elharar Soffer (formerly Ora Meir Soffer), Ilan Ben-Ishay and Ilanit Halperin as members of the Board, and (iii) the transfer of the TechCare’s signatory rights to all Company bank accounts in the name of Citrine S A L Group’s nominee. In addition, the AR Citrine S A L Group Agreement provides for the second tranche of up to the remaining number of shares of common stock that will result in Citrine S A L Group, owning 95 % of the TechCare’s fully diluted capital stock, to be sold conditioned upon the filing of the Company’s previously approved amendment to its First Amended and Restated Certificate of Incorporation to increase the Company’s authorized capital. On January 6, 2020, definitive agreements were executed for the sale of 90 The following table summarizes the assets and liabilities of Novomic as of the deconsolidation date: SUMMARY OF DECONSOLIDATION OF A SUBSIDIARY U.S. Dollars in thousands Cash and cash equivalents 14 Working capital (excluding cash and cash equivalents), net (deficit) (217 ) Long term assets 156 Long term liabilities (5 ) Total value of a subsidiary (52 ) Amounts received - Gain from deconsolidation of a subsidiary $ 52 Commencement of new operations On June 3, 2020 the Company established a wholly owned new Israeli subsidiary: CTGL – Citrine Global Israel Ltd, (the “Israeli Subsidiary”). CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – GENERAL (cont’d) On July 21, 2020, the Israeli Subsidiary began to work with certain Company shareholders, Beezz Home Technologies Ltd., in which Ora Elharar Soffer, the Company’s chairperson and CEO holds shares, and Golden Holdings Neto Ltd., in which Ilan Ben-Ishai, a director of the Company, holds shares, have been working towards establishing an Operational Innovation Center focuses on the medical cannabis industry, CBD, hemp, botanical, food supplements and cosmetics products. The Company’s Board of Directors approved the Israeli Subsidiary to proceed with preparations for entering into an agreement to incorporate a new company, named Cannovation Center Israel Ltd. (“Cannovation”), with Beezz Home Technologies Ltd.and Golden Holdings Neto Ltd., and to accept limitations on the Israeli Subsidiary’s rights in the Cannovation Center if and as mandated under Israeli regulations on the involvement of foreign entities. On August 4, 2020, the Board of the Company approved for the Company and its Israeli Subsidiary to proceed with preparations for investing in iBOT Israel Botanicals Ltd., an Israeli nutritional supplements’ company developing and manufacturing botanical formulas and nutritional supplements for custom & contract manufacturing for leading botanical companies (“iBOT”). iBOT has a manufacturing facility for a wide range of botanical formulations. iBOT’s manufacturing facility is approved by the Israeli Ministry of Health and is GMP-certified, ISO9001-certified and HACCP certified by IQC. The principal shareholders and control persons of iBOT are the Company’s Chief Executive Officer and a Company director. On August 4, 2020, our Board of Directors approved for the Company and Citrine Global Israel to proceed with preparations for investing in iBOT. On August 9, 2021, through our 60 50 thousands 15 thousands 12 lower 25 In October 2021, iBOT granted to Citrine Global Group, a pre-emption right to any equity or equity linked securities that iBOT proposes to issue to an unrelated third party with aggregate gross proceeds to the Company exceeding $1 million or which will result in a change in control in iBOT following such issuance, then iBOT is to give to the Citrine Global Group written notice of such proposed issuance and the relevant terms thereof and the Citrine Global Group shall have ten (10) days thereafter to determine if it elects to purchase a minimum of 51% of the proposed issuance on the price and other terms specified in the notice sent by iBOT (the “Pre-Emption Right”). If the Citrine Global Group elects to exercise the Pre-Emption Right, such purchase is to take place at no more than 90 days following the expiration of the 10 day notice period to the Citrine Global Group. Any iBOT securities of the Pre-Emption Right that Citrine Global Group elects to not purchase are to be sold by not later than 90 days following the end of the Citrine Global Group’s notice period and if such shares are not sold to such third party within the 90 day period, the Pre-Emption right shall apply to any subsequent proposed issuance. The preemption right does not apply to certain specified exceptions. On August 20, 2020, the Israeli Subsidiary, Beezz Home Technologies Ltd., and Golden Holdings Neto Ltd. incorporated Cannovation. Israeli Subsidiary holds 60 % of Cannovation’s shares, while each of Beezz Home Technologies Ltd. and Golden Holdings Neto Ltd. holds 20% of its shares. See note 4 for additional information. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – GENERAL (cont’d) Stock split On November 22, 2020, certain of the Company’s stockholders representing more than 50 % of the Company’s outstanding share capital (the “Majority Consenting Stockholders”) approved an amendment to the Company’s Certificate of Incorporation (the “Reverse Stock Split Certificate of Amendment”) in order to effect a reverse stock split of the Company’s common stock pursuant to a range of between 40-to-1 and 100-to-1 (the “Reverse Stock Split”). Pursuant to the Reverse Stock Split, each forty or one hundred shares of common stock, as shall be determined by the Board at a later time, will be automatically converted, without any further action by the stockholders, into one share of common stock. No fractional shares of common stock will be issued as the result of the Reverse Stock Split. Instead, each stockholder of the Company will be entitled to receive one share of common stock in lieu of the fractional share that would have resulted from the Reverse Stock Split. In addition, the Majority Consenting Stockholders also approved the elimination of the Company’s entire authorized class of fifty million ( 50,000,000 ) undesignated preferred stock, thereby reducing the total number of shares of capital stock that the Company may issue from one billion five hundred fifty-thousand ( 1,550,000,000 ) shares to one billion five hundred thousand ( 1,500,000,000 ) shares, all of which are designated as common stock (the “Certificate of Elimination”). The Certificate of Elimination will be effective upon the filing with the Secretary of the State of Delaware, which was not completed as of the date of this report’s filing. The Reverse Stock Split Certificate of Amendment will be effective upon receipt of approval from the Financial Industry Regulatory Authority (“FINRA”) and the filing with the Secretary of the State of Delaware, both of which were not completed as of the date of the approval of the financial statements. Financial support from shareholders The Company has not yet to generate revenues and is dependent on raising funds from its current shareholders or from other sources. On April 13, 2021, Citrine S A L, on behalf of itself and its affiliates and related parties, has furnished the Company with an irrevocable letter of obligation to financially support the Company until June 30, 2022. On March 17, 2022, Citrine S A L Investment & Holding Ltd. extended this support through June 30, 2023. The Company has no significant firm commitments that require it to remit cash, and can control the level of expenses it incurs. Based on the Company’s current cash balances, and the irrevocable letter of obligation from Citrine S A L noted above, the Company believes it has sufficient funds for its plans for the next twelve months from the issuance of these financial statements. As the Company is embarking on its new activity as detailed herein, it is incurring losses. It cannot determine with reasonable certainty when and if it will have sustainable profits. Patent application On October 20, 2021, the Provisional Patent Application No: 63/257,673 for “PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE-EFFECTS ASSOCIATED WITH THE USE OF CANNABIS, CANNABINOIDS AND RELATED PRODUCTS” was registered at the US Patent and Trademark Office. The patent application describes certain side effects of cannabis use, the needs, technologies, and solutions to support medical cannabis patients who experience side effects related to their cannabis treatment. COVID-19 On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (SARS-CoV-2) to be a global pandemic (COVID-19), which continues to spread throughout the world. The COVID-19 pandemic is having significant effects on global markets, supply chains, businesses, and communities. Specifically with respect to the Company, COVID-19 may impact various parts of its 2022 plans, operations and financial results, including but not limited to difficulties in obtaining additional financing. The Company considered the impact of COVID-19 on the estimates and assumptions and determined that there were no material adverse impacts on the consolidated financial statements for the period ended December 31, 2021 and 2020. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION The financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Principles of Consolidation The accompanying consolidated financial statements include the accounts of Citrine Global and its Israeli Subsidiaries, CTGL - Citrine Global Israel Ltd and Cannovation. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates include share-based compensation and fair value measurements of the convertible notes. Actual results could differ from those estimates. Functional Currency and Foreign Currency Translation and Transactions. Effective May 14, 2020, the Company adopted the U.S. dollar as its functional currency. Prior to May 14, 2020, the functional currency of the Company was the New Israeli Shekel (“NIS”). The change in functional currency of the Company is due to the increased exposure to the U.S. dollar as a result of Sale of the Novomic as described in Note 1 above. Therefore, the currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net loss for the year. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.) Cash, cash equivalents and restricted cash Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired. Restricted cash as of December 31,2021 included a $ 10 thousands collateral account for the Company’s rent agreement and is classified in current assets. Property, plant and equipment, net 1. Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the Statements of Operations and Comprehensive Loss. 2. Rates of depreciation: SCHEDULE OF RATE OF DEPRECIATION OF PROPERTY PLANT AND EQUIPMENT % Computers and office equipment 7 33 Land - Trading securities and short-term loan measured at fair value The Company accounts for its investments in trade securities in accordance with Accounting Standards “ASC”) No. 321, “Investments— Equity Securities.” The Company determines the appropriate classification of its investments in trading securities at the time of purchase and re-evaluates the fair value at each balance sheet date. As of December 31, 2020, all of the Company’s investments in trading securities are classified as held for trade (see also Note 8). Therefore, the Company’s trading securities are recorded at fair value on the balance sheet as well as the short-term loan measured at fair value according to the company’s election. Changes in fair value of trading securities and short-term loan are recorded in financing income (expenses), net in the consolidated statement of operations. The balance of the investments in trading securities as of December 31, 2021 is zero . CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.) Investments valued under the measurement alternative The Company’s investments as described in Notes 3 and 1 are valued under the measurement alternative include equity securities in other proprietary investments for which the Company does not have significant influence and fair value is not readily determinable. Accounting Standard Update (“ASU”) 2016-01 requires equity securities to be recorded at cost and adjusted to fair value at each reporting period. However, the guidance allows for a measurement alternative, which is to record investments at cost, less impairment, if any, and subsequently adjust for observable price changes of identical or similar investments of the same issuer. Due to the lack of readily determinable fair values for such investments, for which the Company does not have significant influence, the Company accounts for these investments under the measurement alternative at cost, less impairment. The Company performs qualitative impairment assessments on its investments recorded under the measurement alternative. Impairment of long-lived assets The Group’s long-lived assets are reviewed for impairment in accordance with ASC Topic 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. No indicators of impairment have been identified as of December 31, 2020 and 2021. Derivatives Derivative instruments are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of financial expenses, net in the statements of operation. Once determined, derivative liabilities and assets are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. Deferred income taxes The Company accounts for income taxes in accordance with ASC Topic 740, “Income Taxes”. Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. The Company accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Company’s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Company did not recognize such items in its fiscal 2021 and 2020 financial statements and did not recognize any liability with respect to an unrecognized tax position in its balance sheets. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.) Research and development expenses Research and development expenses are charged to operations as incurred. Basic and diluted loss per ordinary share Basic loss per share of Common Stock is computed by dividing the loss for the period applicable to holders of shares of Common Stock, by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the shares of Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic loss per share under the two-class method. However, in periods of net loss, only the convertible Preferred Stock are considered, since such shares have a contractual obligation to share in the losses of the Company. In computing diluted loss per share, basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of potential shares. Accordingly, in periods of net loss, no potential shares are considered. Stock-based compensation The Company measures and recognizes the compensation expense for all equity-based payments based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of operation as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.) Fair value Fair value of certain of the Company’s financial instruments including cash, accounts receivable, accounts payable, accrued expenses, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosure,” which defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. Fair value, as defined by ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of nonperformance, which includes, among other things, the Company’s credit risk. Valuation techniques are generally classified into three categories: (i) the market approach; (ii) the income approach; and (iii) the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values. Fair value measurements are required to be disclosed by the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), (ii) segregating those gains or losses included in earnings, and (iii) a description of where those gains or losses included in earning are reported in the statement of operations. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.) As of December 31, 2021, there are no financial assets or financial liabilities that are measured at fair value on a recurring basis. The Company’s financial assets and liabilities as of December 31, 2020 that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows: SCHEDULE OF FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS Level 1 Level 2 Level 3 Total Balance as of December 31, 2020 Level 1 Level 2 Level 3 Total U.S. Dollars in thousands Trading securities (Note 8) - 522 - 522 Short-term loan measured at fair value (Note 8) - - 165 165 Total assets - 522 165 687 Liabilities: Fair value of convertible component in convertible notes (Note 5) - - 381 381 Fair Value of forward option (Note 8) - - 72 72 Total liabilities - - 453 453 The following table presents the changes in fair value of the level 3 liabilities for the year ended December 31, 2021: SCHEDULE OF CHANGES IN FAIR VALUE OF LIABILITIES Changes in Fair value U.S. Dollars in thousands Assets: Outstanding at January 1, 2020 - Fair value of issued level 3 assets 145 Changes in fair value 20 Outstanding at January 1, 2021 165 Outstanding balance 165 Proceeds from repayment of short term loan (164 ) Interest and change in fair value of short-term loan measured at fair value (1 ) Outstanding at December 31, 2021 - Outstanding balance - Liabilities: Outstanding at January 1, 2020 - Fair value of issued level 3 liability 351 Changes in fair value 102 Outstanding at January 1, 2021 453 Outstanding balance 453 Fair value of convertible component in additional convertible notes issued during the period 116 Classification of embedded conversion feature from liability to equity (670 ) Commitment for issuance of fixed number of ordinary shares (14 ) Changes in fair value 115 Outstanding at December 31, 2021 - Outstanding balance - CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.) Concentrations of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in Dollars and New Israeli Shekels, are deposited with major banks in Israel and United States. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Contingencies The Company records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred. Recent Accounting Pronouncements Accounting Pronouncements Not Yet Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and(2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective for public companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2020-06 will have on the Company’s consolidated financial statement presentation or disclosures. Other new pronouncements issued but not effective as of December 31, 2021 are not expected to have a material impact on the Company’s consolidated financial statements. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF RESENTATION (cont.) Reclassification Certain prior year figures have been reclassified to conform to be current year presentation.

INVESTMENT VALUED UNDER THE MEA

INVESTMENT VALUED UNDER THE MEASUREMENT ALTERNATIVE	12 Months Ended
	Dec. 31, 2021
Investment Valued Under Measurement Alternative
INVESTMENT VALUED UNDER THE MEASUREMENT ALTERNATIVE	NOTE 3 - INVESTMENT VALUED UNDER THE MEASUREMENT ALTERNATIVE On June 22, 2020, the Company entered into a share purchase agreement with Nanomedic Technologies Ltd., an Israeli private company and a related party as further described below (“Nanomedic”) as part of an A-1 funding round open only to existing Nanomedic shareholders and their affiliates. Nanomedic developed SpinCare™, a system that integrates electrospinning technology into a portable, bedside device, offering immediate wound and burn care treatment. The Company paid $ 450 3.3 2.2 The Company accounts for the investment in Nanomedic in accordance with the provisions of ASC 321, “Investments - Equity Securities”, and elected to use the measurement alternative therein. The investment will be re-measured upon future observable price change(s) in orderly transaction(s) or upon impairment, if any. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 4 - PROPERTY AND EQUIPMENT, NET SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2021 2020 December 31, 2021 2020 U.S. Dollars in thousands Computers and office equipment 10 6 Land 248 - Property and equipment, gross 258 6 Less - accumulated depreciation (2 ) - (* ) Total property and equipment, net 256 6 In the years ended December 31, 2021 and 2020, depreciation was US$ 2 1 1. On July 13, 2021, the Ministry of Economy of the Israeli government recommended to the Israel Land Authority (“ILA”) that it approve a grant of 11,687 square meters of industrial parcel of land in Yeruham, Israel (the “Land”) for Cannovation to build the Cannovation Center, at a subsidized price and exempt from a tender procedures typically required under Israeli law, to include factories, laboratories, logistics and a distribution center for the medical cannabis, and botanicals industries. As noted, Citrine Global owns 60% of the share capital of Cannovation, through the Israeli Subsidiary. The grant was initially awarded on December 30, 2020 for 10,000 square meters of industrial land in Yeruham, Israel and was increased to 11,687 square meters on July 13, 2021. Cannovation is in process of receiving the required building permits and approvals to start the construction and is in process with several financing entities in the area of real-estate financing. During December 2021, Cannovation remitted to the Israeli Ministry of the Economy and the ILA the aggregate amount of 688 thousand NIS ($ 221 thousands on the date of payment) to obtain the rights to the Land. The discounted amount paid is part of the grant by the Israeli government under government programs to encourage industrial development in Southern Israel. The amount remitted represents the sum total amount that Cannovation is required to pay as the purchase price for the Land. In addition, the Israeli Ministry of Economy is also expected to cover approximately 30% of the building and equipment expenses. Cannovation is also expected to benefit from a reduced corporate tax rate which is intended to encourage industrial development in Southern Israel. Under the Agreement, Cannovation committed to build and develop the Green Vision Center in accordance with the time frames, terms and conditions of the Agreement. Typically, the initial time frame for completing the development is four (4) years, subject to extensions that the ILA may approve. Upon completion of the development within the time frames and other requirements specified in the Agreement, Cannovation will be entitled, subject to Israeli law, to long term lease agreement (49 years) to the Land (equivalent to ownership rights as most of the land in Israel is government owned and when marketed usually the developers are granted with development/long lease rights). The Company has also classified $ 27 thousands of related expenses to land costs. See also note 12B. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
CONVERTIBLE NOTES	NOTE 5 – CONVERTIBLE NOTES A. On April 1, 2020 the Company entered into a Convertible Note Purchase Agreement (the “CL Agreement”) with Citrine S A L , WealthStone Private Equity Ltd, WealthStone Holdings Ltd, Golden Holdings Neto Ltd, Beezz Home Technologies Ltd, Citrine Biotech 5 LP, Citrine High Tech 6 LP, Citrine High Tech 7 LP, Citrine 8 LP, Citrine 9 LP and Citrine Biotech 10 LP (together, the “Buyer”), all of which are affiliated with the Company. Under the CL Agreement, the Buyer agreed to purchase and the Company agreed to issue and sell, for up to an aggregate principal amount of up to $ 1,800 thousand, notes convertible into shares of Common Stock of the Company (the “Notes”), with a drawdown period starting on April 1, 2020 and ending upon the earlier of (i) 6 months thereafter and (ii) the consummation of a public offering by the Company. The CL Agreement provides that the Notes will bear an annual interest rate of six percent ( 6 %) and that the conversion price per share of Common Stock shall equal 85 % multiplied by the market price (as defined in the Notes), representing a discount of 15 %, and that each Note will mature 18 months following the payment date. On April 19, 2020 and June 12, 2020, the Company provided draw down notices under the CL Agreement for amounts of $ 170 1 On June 12, 2020, the CL Agreement was amended (hereafter “Amendment”) to provide that for each draw down made by the Company under the CL Agreement, the Buyer shall be entitled to receive two types of warrants: A warrants and B warrants, with the A warrants exercisable at any time between 6 and 12 months after issuance for an exercise price per share equal to 1.25 times the average of the closing prices of the 3 trading days preceding the draw down, and the B warrants exercisable at any time between 6 and 24 months after issuance for an exercise price per share equal to 1.5 times the average of the closing prices of the 5 trading days preceding the draw down, and that the number of each of the A warrants and the B warrants issued will be equal to the draw down amount divided by the average of the closing prices of the 3 trading days preceding the draw down, and that these amended terms will apply in respect of all draw downs, including drawdowns made prior to the date of the amendment. Conversion feature In accordance with ASC 815-15-25 the conversion feature was considered an embedded derivative instrument, and is to be recorded at its fair value separately from the convertible notes, within current liabilities in the Company’s balance sheet. The conversion component is then marked to market at each reporting period with the resulting gains or losses shown in the statements of operations. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 5 – CONVERTIBLE NOTES The fair value of the conversion feature (hereafter “Convertible Component”) was estimated using the Monte Carlo Simulation Model to compute the Convertible Component’s fair value. The assumptions used to perform the Monte-Carlo simulation model were consistent with those utilized in the Company’s Black-Scholes valuation for stock options are detailed below: SCHEDULE OF FAIR VALUE OF CONVERTIBLE FEATURE USING VALUATION ASSUMPTIONS June 12, 2020 December 31, 2020 Expected volatility (%) 65.69 % 164.43 % Risk-free interest rate (%) 0.18 % 0.1 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 1.5 0.95 Conversion price - (*) - (*) Underlying share price (U.S. dollars) 0.21 0.045 Convertible notes amount 1,275 1,275 Fair value of the conversion feature (U.S. dollars in thousands) 285 381 (*) the conversion price is 85 Warrants As mentioned above, as part of the Amendment, the Company issued to the Buyer 5,589,172 A warrants and 5,589,172 B warrants to purchase a total of 11,178,344 shares of Common Stock of the Company. The fair value of such warrants as of the drawdowns dates was estimated at $ 301,665 The following are the data and assumptions used: SUMMARY OF WARRANTS Warrants A Common Stock price 0.21 Expected volatility 65.31 % Expected term 1 Risk free rate 0.17 % Expected dividend yield 0 % Warrants B Common Stock price 0.21 Expected volatility 68.73 % Expected term 2 Risk free rate 0.19 % Expected dividend yield 0 % Convertible Notes The drawdowns notice amount, net of the Conversion Component and the warrants amounts (hereafter “Convertible notes”), is $ 580 CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 5 – CONVERTIBLE NOTES On April 12, 2021, the parties to the Convertible Note Purchase Agreement (the “CL Agreement”) amended the CL Agreement to (i) change the annual interest on the Notes to nine percent (9%), applicable from January 1, 2021, (ii) ensure that the Company shall repay the loans at the time it consummates an investment in the amount of at least $ 5 million in the Company’s securities, and (iii) modify the exercise prices of each of the A Warrants and B Warrants to $ 0.10 per share, and the term of the A Warrants and B Warrants be extended by one year. The Company concluded that the change in term does not constitute a trouble debt restructuring. Thereafter, the Company applied the guidance in ASC 470-50, Modifications and Extinguishments. The accounting treatment is determined by whether terms of the new debt and original debt are substantially different. The new debt and the old debt are considered “substantially different” pursuant to ASC 470-50 when the present value of the cash flows under the terms of the new debt instrument is at least 10% different from the present value of the remaining cash flows under the terms of the original instrument (including the incremental fair value resulting from the change in the terms of the warrants held by the lender). If the original and new debt instruments are substantially different, the original debt is derecognized and the new debt should be initially recorded at fair value, with the difference recognized as an extinguishment gain or loss. Based on the analysis, the Company concluded that the change in terms should be accounted for as an extinguishment. The extinguishment resulted in a loss of $ 620 thousands (including of $ 361 thousands – change in the fair value of the warrants which is considered transaction cost). The fair value of the warrants was estimated using the Black-Scholes option pricing model. The assumptions used to perform the calculations are detailed below: Fair value of the warrants immediately before the change: SCHEDULE OF FAIR VALUE OF WARRANT USING ASSUMPTIONS Fair value of the warrants A Warrant B Warrant Expected volatility (%) 150.5 % 158.7 % Risk-free interest rate (%) 0.04 % 0.08 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 0.18 1.18 Conversion price 0.26 0.31 Underlying share price (U.S. dollars) 0.07 0.07 Fair value (U.S. dollars in thousands) 3 121 Fair value of the warrants immediately after the change: Fair value of the warrants A Warrant B Warrant Expected volatility (%) 158.7 % 158.7 % Risk-free interest rate (%) 0.08 % 0.22 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 1.18 2.18 Conversion price 0.1 0.1 Underlying share price (U.S. dollars) 0.07 0.07 Fair value (U.S. dollars in thousands) 211 274 CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 5 – CONVERTIBLE NOTES B. On June 24, 2021, the Company received from Citrine 8 LP, a related party, a convertible loan of $ 350 thousands made under and pursuant to the CL Agreement. Citrine agreed to honor a Draw Down Notice for, and advanced to the Company, $ 350 thousands, under the terms of the CL Agreement. As provided for under the terms of the CL Agreement, Citrine 8 LP was also issued 10,500,105 A warrants and 10,500,105 B warrants for shares of common stock, where the A warrants are exercisable beginning December 24, 2021 through December 24, 2023 and the B warrants, in each case at a per share exercise price of $ 0.10 (the “June 24 Agreement”). Convertible Component of the Loan The fair value of the conversion feature (hereafter “Convertible Component”) was estimated using the Monte Carlo Simulation Model to compute the Convertible Component’s fair value. The assumptions used to perform the Monte-Carlo simulation model on June 24, 2021 were consistent with those utilized in the Company’s Black-Scholes valuation for stock options are detailed below: SCHEDULE OF FAIR VALUE OF OPTION USING ASSUMPTIONS June 24, 2021 Expected volatility (%) 156.8 % Risk-free interest rate (%) 0.17 % Expected dividend yield 0.0 % Contractual term (years) 1.5 Conversion price - Underlying share price (US dollars) 0.03 Convertible notes amount 397 Fair value of the conversion feature (US dollars in thousands) 117 (*) the conversion price is 85% of the share price, during the period of 5 days preceding the conversion date. Warrants The fair value of such warrants granted as part of the June 24 agreement was estimated at $ 404 thousands using the Black-Scholes option-pricing model and recorded as additional paid-in capital on the balance sheet. The assumptions used to perform the calculations are detailed below: SCHEDULE OF FAIR VALUE OF WARRANT USING ASSUMPTIONS A Warrant B Warrant Expected volatility (%) 156.8 % 156.8 % Risk-free interest rate (%) 0.37 % 0.59 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 2.5 3.5 Conversion price 0.1 0.1 Underlying share price (U.S. dollars) 0.03 0.03 Fair value (U.S. dollars in thousands) 184 220 CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (U.S. dollars in thousands) NOTE 5 – CONVERTIBLE NOTES Fair Value Proportional Allocation for the June 24 Loan The fair value of the note was estimated at $ 308 thousands . The note is accounted for according to the effective interest method. Based on the above, the fair value proportion allocation as of June 24, 2021 was as follows: SCHEDULE OF FAIR VALUE OF DEBT June 24, 2021 (US dollars in thousands) Conversion Component $ 117 Warrants 172 Convertible Notes 61 Total $ 350 C. On August 13, 2021, the Company and the holders of $ 1,520 (i) Extension of the maturity date on the Outstanding CL Notes to July 31, 2023 5 (ii) Amendment of the conversion price on the Outstanding CL Notes to a fixed conversion price of $ 0.10 (iii) Confirming the agreement of the holders of the Outstanding CL Notes to honor draw down notice for balance of remainder of the $1,800 thousands originally committed to under the CL Agreement (i.e., $280 thousands) through March 31, 2022. The Company concluded that the change in term constitutes a trouble debt restructuring, due to its financial condition and the relief that the abovementioned changes provided. A new effective interest rate was established based on the carrying value of the debt and the revised cash flows. Following the abovementioned amendment on August 13, 2021, the conversion component is qualifying for the scope exception under ASC 815-10-15-74(a). In accordance with ASC 815-15-35-4, since the embedded conversion option in the convertible debt no longer meets the bifurcation criteria, the fair value of the conversion component, in the amount of $ 670,224 Conversion feature CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 5 – CONVERTIBLE NOTES The fair value of the conversion feature (hereafter “Convertible Component”) was estimated using the Monte-Carlo simulation model to compute the Convertible Component’s fair value. The assumptions used to perform the Monte-Carlo simulation model were consistent with those utilized in the Company’s Black-Scholes valuation for stock options are detailed below: Loan #1 that was amended on August 13, 2021: August 13, 2021 December 31, 2020 Expected volatility (%) 149.04 % 164.43 % Risk-free interest rate (%) 0.05 % 0.1 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 0.34 0.95 Conversion price - (*) - (*) Underlying share price (U.S. dollars) 0.05 0.045 Convertible notes amount 1,312 1,275 Fair value of the conversion feature (U.S. dollars in thousands) 379 381 (*) the conversion price is 85 Loan #2 that was amended on August 13, 2021: August 13, 2021 June 24, 2021 Expected volatility (%) 151.48 % 156.8 % Risk-free interest rate (%) 0.13 % 0.17 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 1.36 1.5 Conversion price - (*) - (*) Underlying share price (U.S. dollars) 0.05 0.3 Convertible notes amount 397 397 Fair value of the conversion feature (U.S. dollars in thousands) 115 117 (*) the conversion price is 85 Following the abovementioned amendment on August 13, 2021, the conversion component is qualifying for the scope exception under ASC 815-10-15-74(a). In accordance with ASC 815-15-35-4, since the embedded conversion option in the convertible debt no longer meets the bifurcation criteria, the fair value of the conversion component, in the amount of $ 670 thousands , was reclassified from short-term liability to shareholders equity at that date. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SHAREHOLDERS_ EQUITY

SHAREHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 6 – SHAREHOLDERS’ EQUITY Description of the rights attached to the Shares in the Company: Common Stock: Each share of Common Stock entitles the holder to one vote, either in person or by proxy, at meetings of stockholders. The holders of Common Stock are not permitted to vote their shares cumulatively. Accordingly, the holders of the Company’s Common Stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of the directors and, in such event, the holders of the remaining minority shares will not be able to elect any of such directors. The vote of the holders of a majority of the issued and outstanding shares of Common Stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law. Transactions: On January 29, 2020, holders of 10,344,828 redeemable convertible Series A Preferred Stock, converted their shares into 10,344,828 shares of Common Stock . The terms of the transaction for the issuance of 893,699,276 432,996,555 0.0001 445,702,721 893,699,276 On March 5, 2020 the Company issued 15,000,000 shares of Common Stock to its legal advisor in respect of legal consulting services, with respect to the Citrine Global Transaction as well as other legal services, as agreed between the parties. The Company estimated the fair value of the shares issued based on the share price at the grant date at $ 4,785 thousand. During the years ended December 31, 2021 and 2020 the Company recorded share based compensation expense of $ 1,034 thousands and $ 3,751 thousands , respectively, among general and administrative expenses. On November 11, 2020, the Company issued additional 13,222,082 shares of Common Stock to its legal advisor pursuant to the above agreement. The Company estimated the fair value of the shares issued based on the share price at the grant date at $ 4,218 thousand. During the years ended December 31, 2021 and 2020 the Company recorded share based compensation expense of $ 703 thousands and $ 3,515 thousands , respectively, among general and administrative expenses. On May 14, 2020 the Company amended its Certificate of Incorporation to reflect the increase of its authorized capital by one billion shares of Common Stock On November 11, 2020, the Company issued 1,411,104 155 On October 8, 2020, the Board approved a reverse stock split of the Company’s authorized, issued and outstanding shares of Common Stock, at a ratio between 1-for-40 to 1-for-100, subject to the approval of the Company’s stockholders (the “Reverse Stock Split”). The final ratio of the Reverse Stock Split will be determined by the Board at a later date. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS On November 8, 2020, the Board approved an amendment to its Certificate of Incorporation to remove from its authorized capital stock of the Company the fifty million (50,000,000)

STOCK OPTIONS

STOCK OPTIONS	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK OPTIONS	NOTE 7 – STOCK OPTIONS A. On August 15, 2021, the Company’s board of directors determined to increase the number of shares reserved for issuance under the 2018 Stock Incentive Plan to 90,000,000 9,425,680 2,365,420 0.05 On December 29, 2021 the Company’s board of directors approved the grants of the options. The fair value at December 29, 2021 was determined using the Black-Scholes pricing model, assuming a risk free rate of 1.29 %, a volatility factor of 152.1 %, dividend yields of 0 % and an expected life of 5 years. The Company estimated the fair value of each option granted at December 29, 2021 at $ 0.022 519 thousands. Total share based compensation expenses during the year ended December 31, 2021 amounted to $ 456 thousands . The remaining expense of $ 63 0.5 The following table presents the Company’s stock option activity for employees and directors of the Company for the years ended December 31, 2021 and 2020: SCHEDULE OF STOCK OPTION ACTIVITY Number of Options Weighted Average Exercise Price Outstanding at January 1, 2020 521,065 0.0011 Granted - - Exercised - - Forfeited or expired (474,303 ) 0.0011 Outstanding at December 31, 2020 46,762 0.0011 Granted 23,582,200 0.05 Exercised - - Forfeited or expired - - Outstanding at December 31, 2021 23,628,962 0.05 Number of options exercisable at December 31, 2021 15,672,670 0.05 The intrinsic value of options outstanding and exercisable at December 31, 2021 totaled $ 1 During 2020, an amount 28,222,082 1,411,104 CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AGREEMENTS WITH INTELICANNA LTD

AGREEMENTS WITH INTELICANNA LTD	12 Months Ended
	Dec. 31, 2021
Agreements With Intelicanna Ltd
AGREEMENTS WITH INTELICANNA LTD	NOTE 8 – AGREEMENTS WITH INTELICANNA LTD A. On May 31, 2020, the Company entered into a strategic partnership with Intelicanna Ltd., an Israeli medical cannabis company listed on the Tel Aviv Stock Exchange with ticker symbol INTL (“Intelicanna”), via a share exchange agreement (the “Share Exchange Agreement”) and an agreement for future issuance of shares (the “Agreement for Future Issuance of Shares”). The Share Exchange Agreement provides that (i) the number of shares each party issues to the other will be calculated by dividing $500 thousand by the volume weighted average price (VWAP) of the issuing party’s shares in the three trading days preceding the signing of the agreement, (ii) the issuance by Intelicanna will take place upon, and subject to, receipt of approval from the Tel Aviv Stock Exchange, and the issuance by the Company will follow immediately thereafter, and (iii) the parties may not sell the shares within the first six months after issuance, and thereafter the parties may sell the shares issued to them if the shares become registered through a prospectus approved by the relevant securities authority, or under an exemption provided by applicable securities law, subject to a limit on the number of shares either party may sell per day. The Agreement for future Issuance of Shares provides that a fall in a share price of a party, not exceeding 20%, measured six months after issuance of shares by both parties pursuant the Share Exchange Agreement, will be offset by the issuance of additional shares to the other party to bring up to $500 thousand the total value of the shares issued to the other party. On August 15, 2021, the Company’s board of directors determined that it is required to issue to Intelicanna 619,589 shares of the Company’s common stock and has authorized the issuance of such shares to Intelicanna. As of December 31, 2021, the common stock have not been issued yet. As such, the Company recorded an additional $14 thousands to be issued to Intellicanna. On September 17, 2020 the Company issued to Intelicanna 2,143,470 619,589 50 The fair value of such shares exchange agreement was estimated using the Black-Scholes option-pricing model and is presented among current liabilities within the Company’s consolidated balance sheet. The following are the data and assumptions used as of the balance sheet date related to future potential issuance of shares as describe above for potential fall in share price of a party, not exceeding 20%: SCHEDULE OF FAIR VALUE OF SHARES EXCHANGE AGREEMENT Derivative related to Intelicanna’s shares December 31, 2020 Common Stock price 0.83 Expected volatility 57.61 % Conversion price (U.S. dollars) 0.64 Expected term 3.1 Risk free rate 0.09 % Expected dividend yield 0 % Fair value of the derivative (U.S. dollars in thousands) 28 Derivative related to Citrine Global’s shares December 31, 2020 Common Stock price 0.046 Expected volatility 125.19 % Conversion price (U.S. dollars) 0.2 Expected term 3.1 Risk free rate 0.09 % Expected dividend yield 0 % Fair value of the derivative (U.S. dollars in thousands) (100 ) CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Between August 3 – 9, 2021, the Company sold to an unrelated third party in an off market transaction 619,589 ordinary shares of Intelicanna Ltd., an Israeli medical cannabis company listed on the Tel Aviv Stock Exchange (“Intelicanna”), for aggregate gross proceeds to the Company of 1,261,000 NIS (approximately $ 389 thousands based on the current exchange rate). Following the sale, the Company no longer holds any Intelicanna shares. B. Furthermore, on June 25, 2020, the Israeli Subsidiary entered into a services agreement with Intelicanna to provide business development and consulting services to Intelicanna, including assistance with raising financing (the “Services Agreement”) (references in this paragraph to the Company include the Israeli Subsidiary). The terms of the Services Agreement include: (1) the Company will, for a period of 18 months, assist Intelicanna to raise up to NIS 15 2,500 On October 5, 2021 the Company and Intelicanna mutually terminated the Service Agreement. C . Also on June 25, 2020, the Company and the Israeli Subsidiary entered into an agreement to grant Intelicanna Ltd. (“Intelicanna”) New Israeli Shekel (“NIS”) 1 290 6% 2 600 12% 1.5 0.45 CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS The financing must be paid by the Company to Intelicanna within 30 days of signing the financing agreement, subject to completion of due diligence to the Company’s satisfaction and to Intelicanna receiving a commercial growing license. On July 9, 2020, the Company transferred to Intelicanna NIS 500 145 As of December 31, 2021, Intelicanna repaid the full principal of the loan together with 12 46 14 Ilanit Halperin, a director and the Chief Financial Officer of the Company, is also the Chief Financial Officer of Intelicanna. Doron Birger, a director at the Company, is also the chairman of the board of directors of Intelicanna, effective March 30, 2022.

RELATED PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 9 – RELATED PARTIES A. Transactions and balances with related parties SCHEDULE OF TRANSACTIONS AND BALANCES WITH RELATED PARTIES Year ended December 31 2021 2020 U.S. Dollars in thousands Research and development expenses: Fees to officers 48 - Other expenses 26 - 74 - General and administrative expenses: Directors compensation and fees to officers (*) 919 496 (*) Share based compensation 404 - Financing expenses , net: Financial expenses related to convertible loan 1,129 287 Interest on loan (**) - - (**) Less than 1 thousand CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS B. Balances with related parties: As of December 31, 2021 2020 U.S. Dollars in thousands Current Assets: Short term loan 15 - Current Liabilities: Convertible notes 1,431 773 Accounts payable 20 312 Accrued compensation 838 - C. Commencing in February 2020, Ora Elharar Soffer, CEO and Chairperson of the Board, was entitled to a monthly fee of $ 20 thousands and certain reimbursements for traveling, lodging and other expenses on behalf of the Company, the payment of such compensation was deferred until the Company consummates an investment of at least $ 1.8 In addition, on August 15, 2021, the board of directors of Cannovation determined to adjust the compensation of the Chairperson (and interim Chief Executive Officer), Ora Elharar Soffer, to $10 thousands per month, in each case retroactive to July 1, 2021. These amounts would be paid at such time as Cannovation shall become due and payable from, and such time as Cannovation shall have, available funds therefor and as part of the operating budget for a minimum period of 18 months. As of December 31, 2021, and 2020, an amount of $ 499 210 D. Commencing in February 2020, Ilan Ben-Ishay, a director, is entitled to a monthly fee of $ 4 1.8 In addition, on August 15, 2021, the board of directors of Cannovation determined to adjust the compensation of Ilan Ben-Ishay, a director at Cannovation, to $ 2 shall have, available funds therefor and as part of the operating budget for a minimum period of 18 months. As of December, 31, 2021, and 2020, an amount of $ 86 34 representing compensation earned by Mr. Ben-Ishay. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS E. Commencing in May 2020, Ms. Halperin, CFO of the Company, was entitled to a monthly fee of an additional $ 4 In addition, on August 15, 2021, the board of directors of Cannovation determined to adjust the compensation of the chief financial officer, Ilanit Halperin at Cannovation, to $ 4 As of December, 31, 2021, and 2020, an amount of $ 171 66 representing compensation earned by Ms. Halperin. F. Commencing in March 2021, Adv. David Kretzmer, a director, is entitled to a monthly fee of $ 7 thousand and certain reimbursements for traveling lodging and vehicle expenses on behalf of the Company, the payment of such compensation was deferred until the Company consummates an investment of at least $1.8 million in the Company’s securities. In addition, on August 15, 2021, the board of directors of Cannovation determined to adjust the compensation of David Kretzmer, a director at Cannovation, to $2 thousands per month, in each case retroactive to July 1, 2021. These amounts would be paid at such time as Cannovation shall become due and payable from, and such time as Cannovation shall have, available funds therefor and as part of the operating budget for a minimum period of 18 months. As of December, 31, 2021, an amount of $82 thousands representing compensation earned by Adv. David Kretzmer. G. On August 15, 2021, the board determined to award a bonus to the Company’s Chairperson of the Board, CEO, CFO, officers, directors and senior management equal to two percent (2%) of any capital raise, subject to prior repayment of the outstanding convertible loans and so long as the payment thereof would be from available funds and part of the Company’s operating budget for a minimum period of 18 months. In addition, the Board agreed to a bonus Company’s Chairperson of the Board, CEO, CFO, officers, directors and senior management of 2% from operating profits which will become payable upon the fulfillment of certain specified targets that the Board will establish, subject to prior repayment of the outstanding convertible loans and so long as the payment thereof would be from available funds and as part of the Company’s operating budget for a minimum period of 18 months. H. On August 9, 2021, through its 60 I. On September 29, 2021, Citrine Global advanced to iBOT, a related party, a loan of $ 50 thousands with a 12 month maturity date . The loan bears interest at an effective annual interest rate of 12 % as and is convertible, at the option of Citrine Global, into equity shares of iBOT at conversion rate equal to the lower of (i) 25 % discount to the most recent round of capital raised by iBOT during the term of the loan and (ii) the rate specified in the framework agreement. In addition, Citrine Global is entitled to convert the outstanding loan, in whole or in part, to satisfy payments of amounts owed to iBOT under the services agreements between the parties. On October 8, 2021 the Company transferred a first tranche of $15 thousands. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS J. On November, 2021, the Company, Cannovation and CTGL – Citrine Global Israel Ltd., on the one hand (collectively the “Citrine Global Group”), and iBOT, on the other hand, entered into an Exclusive Strategic Collaboration and Alliance Agreement (the “Exclusive Rights Agreement”) pursuant to which iBOT granted to the Citrine Global Group, jointly and individually, exclusive world-wide rights, solely with respect to the cannabis market, to iBOT’s botanical formulas and nutritional supplements, including, the development, manufacture, distribution and sale of such products. The exclusive rights include the right of any of the Citrine Global Group to grant rights thereunder to third parties so long as such third parties shall agree to be bound by terms consistent with those contained in this Agreement. In consideration of the grant of the rights under the Exclusive Rights Agreement, Citrine Global Group granted to iBOT the exclusive right to manufacture in State of Israel (consistent with the terms of the Manufacturing Agreement) the botanical products. In addition, so long as iBOT is in compliance with the terms of this Agreement, in the event that the Citrine Global Group determines to manufacture botanical products outside of Israel, then iBOT is to be afforded the opportunity to perform such manufacturing for the Citrine Group at iBOT’s facility in Israel provided that iBOT complies with all of the terms and conditions relating to such manufacturing project, including the price per unit, delivery schedules, packaging requirements regulation and other relevant terms. K. See also Note 7A. L. See also Note 5.

INCOME TAX

INCOME TAX	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 10 – INCOME TAX A. United States resident companies are taxed on their worldwide income for corporate income tax purposes at a statutory rate of 21 Income of the Israeli Subsidiary is taxable from 2018 and onwards, at corporate tax rate of 23 The Company and its Israeli Subsidiary have not received final tax assessments since the Israeli Subsidiary’s inception. As of December 31, 2021, the Company and the Israeli Subsidiaries have carryforward losses for tax purposes of approximately $ 3,954 337 CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS B. Composition of loss for the year: SCHEDULE OF COMPOSITION OF LOSS Year ended December 31 2021 2020 U.S. Dollars in thousands U.S. 4,172 8,583 Israel 344 56 Total 4,516 8,639 C. The following is reconciliation between the theoretical tax on pre-tax income, at the tax rate applicable to the Company (federal tax rate) and the tax expense reported in the financial statements: SCHEDULE OF RECONCILIATION OF EFFECTIVE TAX RATE 2021 2020 Year ended December 31 2021 2020 U.S. Dollars in thousands Pretax loss 4,516 8,639 Federal tax rate 21 % 21 % Income tax benefit computed at the ordinary tax rate (948 ) (1,814 ) Non-deductible expenses 2 1 Stock-based compensation 96 1,559 Fair value adjustments 246 41 Tax in respect of differences in corporate tax rates (6 ) (1 ) Change in valuation allowance 610 214 Total Income tax - - D. Deferred taxes result primarily from temporary differences in the recognition of certain revenue and expense items for financial and income tax reporting purposes. Significant components of the Company’s future tax assets are as follows: SCHEDULE OF DEFERRED TAX ASSETS C 2021 2020 Year ended December 31 2021 2020 U.S. Dollars in thousands Composition of deferred tax assets: Non capital loss carry forwards 908 362 Other timing differences 64 - Valuation allowance (972 ) (362 ) Total deferred tax assets - - E. Roll forward of valuation allowance SCHEDULE OF ROLL FORWARD OF VALUATION ALLOWANCE U.S. Dollars in thousands Balance at January 1, 2020 2,041 Sale of subsidiary (1,893 ) Income tax expense 214 Balance at December 31, 2020 362 Income tax expense 610 Balance at December 31, 2021 972

LOSS PER ORDINARY SHARE

LOSS PER ORDINARY SHARE	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
LOSS PER ORDINARY SHARE	NOTE 11 – LOSS PER ORDINARY SHARE Basic loss per share is computed by dividing net loss by the weighted average number of shares outstanding during the year. The weighted average number of shares of Common Stock used in computing basic and diluted loss per ordinary share for the years ended December 31, 2021 and 2020, are as follows: SCHEDULE OF BASIC AND DILUTED LOSS PER ORDINARY SHARE Year ended December 31 2021 2020 Number of shares Weighted average number of shares of Common Stock outstanding attributable to ordinary shareholders 942,568,006 476,622,892 Total weighted average number of shares of Common Stock related to outstanding options, excluded from the calculations of diluted loss per share (*) 15,672,670 46,762 (*) The effect of the inclusion of options and convertible loans in 2021 and 2020 is anti-dilutive. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS A. On January 5, 2022, Citrine 9 LP, one of the Buyer entities (hereinafter “Citrine 9”) agreed to honor a Draw Down Notice (as defined in the Convertible Note Agreement) for, and has advanced to the Company, $ 180 thousands on the same terms and conditions as are specified in the Convertible Note Agreement (see note 5A above). The maturity date of the loan is the earlier of July 31, 2023 or at such time as the Company shall have consummated an investment of at least $ 5 million in Company securities. The annual interest on the loan continues to be nine percent ( 9 %). The principal and interest payment on the Note shall be made in New Israeli Shekels (NIS) at the conversion rate which was in effect on the date on which the loan was advanced. As provided for under the terms of the Convertible Note Agreement, Citrine 9 will be issued 6,666,667 Series A warrants and 6,666,667 Series B warrants for shares of common stock, where the Series A warrants are exercisable beginning July 5, 2022 through July 5, 2024 and the Series B warrants are exercisable beginning July 5, 2022 through July 5, 2025, in each case at an exercise price of $ 0.05 Additionally, on January 5, 2022, the Company and the Buyers entered into the Fourth Amendment to the Convertible Note Agreement pursuant to which the following was agreed to: (i) The principal and accrued interest on all outstanding loans shall be made in New Israeli Shekels (NIS) at the conversion rate which was in effect on the date on which the loan was advanced; (ii) The conversion price on all outstanding notes under the Convertible Note Agreement has been adjusted to a conversion price of $ 0.05 (iii) The exercise price on all outstanding warrants issued in connection with advances made under the Convertible Note Agreement has been adjusted to an exercise price of $ 0.05 B. On February 8, 2022, Cannovation Ltd received from ILA a counter-signed development agreement to purchase rights for long term lease to 11,687 square meters of Land for purposes of building the Green Vision Center Israel, which is intended to include factories, laboratories, logistics and a distribution center for the medical cannabis, and botanicals industries. C. On March 30, 2022, the Company Board determined to allot the Bonus referred to in Note 9G as follows: 65% of such bonus amounts were allocated to the Company’s Chief Executive Officer, 25% to the Company’s Chief Financial Officer and 5% to one of the directors

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Citrine Global and its Israeli Subsidiaries, CTGL - Citrine Global Israel Ltd and Cannovation. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates include share-based compensation and fair value measurements of the convertible notes. Actual results could differ from those estimates.
Functional Currency and Foreign Currency Translation and Transactions.	Functional Currency and Foreign Currency Translation and Transactions. Effective May 14, 2020, the Company adopted the U.S. dollar as its functional currency. Prior to May 14, 2020, the functional currency of the Company was the New Israeli Shekel (“NIS”). The change in functional currency of the Company is due to the increased exposure to the U.S. dollar as a result of Sale of the Novomic as described in Note 1 above. Therefore, the currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net loss for the year. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.)
Cash, cash equivalents and restricted cash	Cash, cash equivalents and restricted cash Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired. Restricted cash as of December 31,2021 included a $ 10 thousands collateral account for the Company’s rent agreement and is classified in current assets.
Property, plant and equipment, net	Property, plant and equipment, net 1. Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the Statements of Operations and Comprehensive Loss. 2. Rates of depreciation: SCHEDULE OF RATE OF DEPRECIATION OF PROPERTY PLANT AND EQUIPMENT % Computers and office equipment 7 33 Land -
Trading securities and short-term loan measured at fair value	Trading securities and short-term loan measured at fair value The Company accounts for its investments in trade securities in accordance with Accounting Standards “ASC”) No. 321, “Investments— Equity Securities.” The Company determines the appropriate classification of its investments in trading securities at the time of purchase and re-evaluates the fair value at each balance sheet date. As of December 31, 2020, all of the Company’s investments in trading securities are classified as held for trade (see also Note 8). Therefore, the Company’s trading securities are recorded at fair value on the balance sheet as well as the short-term loan measured at fair value according to the company’s election. Changes in fair value of trading securities and short-term loan are recorded in financing income (expenses), net in the consolidated statement of operations. The balance of the investments in trading securities as of December 31, 2021 is zero . CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.)
Investments valued under the measurement alternative	Investments valued under the measurement alternative The Company’s investments as described in Notes 3 and 1 are valued under the measurement alternative include equity securities in other proprietary investments for which the Company does not have significant influence and fair value is not readily determinable. Accounting Standard Update (“ASU”) 2016-01 requires equity securities to be recorded at cost and adjusted to fair value at each reporting period. However, the guidance allows for a measurement alternative, which is to record investments at cost, less impairment, if any, and subsequently adjust for observable price changes of identical or similar investments of the same issuer. Due to the lack of readily determinable fair values for such investments, for which the Company does not have significant influence, the Company accounts for these investments under the measurement alternative at cost, less impairment. The Company performs qualitative impairment assessments on its investments recorded under the measurement alternative.
Impairment of long-lived assets	Impairment of long-lived assets The Group’s long-lived assets are reviewed for impairment in accordance with ASC Topic 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. No indicators of impairment have been identified as of December 31, 2020 and 2021.
Derivatives	Derivatives Derivative instruments are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of financial expenses, net in the statements of operation. Once determined, derivative liabilities and assets are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.
Deferred income taxes	Deferred income taxes The Company accounts for income taxes in accordance with ASC Topic 740, “Income Taxes”. Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. The Company accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Company’s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Company did not recognize such items in its fiscal 2021 and 2020 financial statements and did not recognize any liability with respect to an unrecognized tax position in its balance sheets. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.)
Research and development expenses	Research and development expenses Research and development expenses are charged to operations as incurred.
Basic and diluted loss per ordinary share	Basic and diluted loss per ordinary share Basic loss per share of Common Stock is computed by dividing the loss for the period applicable to holders of shares of Common Stock, by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the shares of Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic loss per share under the two-class method. However, in periods of net loss, only the convertible Preferred Stock are considered, since such shares have a contractual obligation to share in the losses of the Company. In computing diluted loss per share, basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of potential shares. Accordingly, in periods of net loss, no potential shares are considered.
Stock-based compensation	Stock-based compensation The Company measures and recognizes the compensation expense for all equity-based payments based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of operation as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.)
Fair value	Fair value Fair value of certain of the Company’s financial instruments including cash, accounts receivable, accounts payable, accrued expenses, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosure,” which defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. Fair value, as defined by ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of nonperformance, which includes, among other things, the Company’s credit risk. Valuation techniques are generally classified into three categories: (i) the market approach; (ii) the income approach; and (iii) the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values. Fair value measurements are required to be disclosed by the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), (ii) segregating those gains or losses included in earnings, and (iii) a description of where those gains or losses included in earning are reported in the statement of operations. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.) As of December 31, 2021, there are no financial assets or financial liabilities that are measured at fair value on a recurring basis. The Company’s financial assets and liabilities as of December 31, 2020 that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows: SCHEDULE OF FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS Level 1 Level 2 Level 3 Total Balance as of December 31, 2020 Level 1 Level 2 Level 3 Total U.S. Dollars in thousands Trading securities (Note 8) - 522 - 522 Short-term loan measured at fair value (Note 8) - - 165 165 Total assets - 522 165 687 Liabilities: Fair value of convertible component in convertible notes (Note 5) - - 381 381 Fair Value of forward option (Note 8) - - 72 72 Total liabilities - - 453 453 The following table presents the changes in fair value of the level 3 liabilities for the year ended December 31, 2021: SCHEDULE OF CHANGES IN FAIR VALUE OF LIABILITIES Changes in Fair value U.S. Dollars in thousands Assets: Outstanding at January 1, 2020 - Fair value of issued level 3 assets 145 Changes in fair value 20 Outstanding at January 1, 2021 165 Outstanding balance 165 Proceeds from repayment of short term loan (164 ) Interest and change in fair value of short-term loan measured at fair value (1 ) Outstanding at December 31, 2021 - Outstanding balance - Liabilities: Outstanding at January 1, 2020 - Fair value of issued level 3 liability 351 Changes in fair value 102 Outstanding at January 1, 2021 453 Outstanding balance 453 Fair value of convertible component in additional convertible notes issued during the period 116 Classification of embedded conversion feature from liability to equity (670 ) Commitment for issuance of fixed number of ordinary shares (14 ) Changes in fair value 115 Outstanding at December 31, 2021 - Outstanding balance - CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.)
Concentrations of credit risk	Concentrations of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in Dollars and New Israeli Shekels, are deposited with major banks in Israel and United States. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Contingencies	Contingencies The Company records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Pronouncements Not Yet Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and(2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective for public companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2020-06 will have on the Company’s consolidated financial statement presentation or disclosures. Other new pronouncements issued but not effective as of December 31, 2021 are not expected to have a material impact on the Company’s consolidated financial statements. CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF RESENTATION (cont.)
Reclassification	Reclassification Certain prior year figures have been reclassified to conform to be current year presentation.

GENERAL (Tables)

GENERAL (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF DECONSOLIDATION OF A SUBSIDIARY	The following table summarizes the assets and liabilities of Novomic as of the deconsolidation date: SUMMARY OF DECONSOLIDATION OF A SUBSIDIARY U.S. Dollars in thousands Cash and cash equivalents 14 Working capital (excluding cash and cash equivalents), net (deficit) (217 ) Long term assets 156 Long term liabilities (5 ) Total value of a subsidiary (52 ) Amounts received - Gain from deconsolidation of a subsidiary $ 52

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SCHEDULE OF RATE OF DEPRECIATION OF PROPERTY PLANT AND EQUIPMENT	SCHEDULE OF RATE OF DEPRECIATION OF PROPERTY PLANT AND EQUIPMENT % Computers and office equipment 7 33 Land -
SCHEDULE OF FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS	SCHEDULE OF FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS Level 1 Level 2 Level 3 Total Balance as of December 31, 2020 Level 1 Level 2 Level 3 Total U.S. Dollars in thousands Trading securities (Note 8) - 522 - 522 Short-term loan measured at fair value (Note 8) - - 165 165 Total assets - 522 165 687 Liabilities: Fair value of convertible component in convertible notes (Note 5) - - 381 381 Fair Value of forward option (Note 8) - - 72 72 Total liabilities - - 453 453
SCHEDULE OF CHANGES IN FAIR VALUE OF LIABILITIES	The following table presents the changes in fair value of the level 3 liabilities for the year ended December 31, 2021: SCHEDULE OF CHANGES IN FAIR VALUE OF LIABILITIES Changes in Fair value U.S. Dollars in thousands Assets: Outstanding at January 1, 2020 - Fair value of issued level 3 assets 145 Changes in fair value 20 Outstanding at January 1, 2021 165 Outstanding balance 165 Proceeds from repayment of short term loan (164 ) Interest and change in fair value of short-term loan measured at fair value (1 ) Outstanding at December 31, 2021 - Outstanding balance - Liabilities: Outstanding at January 1, 2020 - Fair value of issued level 3 liability 351 Changes in fair value 102 Outstanding at January 1, 2021 453 Outstanding balance 453 Fair value of convertible component in additional convertible notes issued during the period 116 Classification of embedded conversion feature from liability to equity (670 ) Commitment for issuance of fixed number of ordinary shares (14 ) Changes in fair value 115 Outstanding at December 31, 2021 - Outstanding balance -

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2021 2020 December 31, 2021 2020 U.S. Dollars in thousands Computers and office equipment 10 6 Land 248 - Property and equipment, gross 258 6 Less - accumulated depreciation (2 ) - (* ) Total property and equipment, net 256 6

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	12 Months Ended
	Dec. 31, 2021
SCHEDULE OF FAIR VALUE OF CONVERTIBLE FEATURE USING VALUATION ASSUMPTIONS	The fair value of the conversion feature (hereafter “Convertible Component”) was estimated using the Monte Carlo Simulation Model to compute the Convertible Component’s fair value. The assumptions used to perform the Monte-Carlo simulation model were consistent with those utilized in the Company’s Black-Scholes valuation for stock options are detailed below: SCHEDULE OF FAIR VALUE OF CONVERTIBLE FEATURE USING VALUATION ASSUMPTIONS June 12, 2020 December 31, 2020 Expected volatility (%) 65.69 % 164.43 % Risk-free interest rate (%) 0.18 % 0.1 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 1.5 0.95 Conversion price - (*) - (*) Underlying share price (U.S. dollars) 0.21 0.045 Convertible notes amount 1,275 1,275 Fair value of the conversion feature (U.S. dollars in thousands) 285 381 (*) the conversion price is 85
SUMMARY OF WARRANTS	The following are the data and assumptions used: SUMMARY OF WARRANTS Warrants A Common Stock price 0.21 Expected volatility 65.31 % Expected term 1 Risk free rate 0.17 % Expected dividend yield 0 % Warrants B Common Stock price 0.21 Expected volatility 68.73 % Expected term 2 Risk free rate 0.19 % Expected dividend yield 0 %
SCHEDULE OF FAIR VALUE OF WARRANT USING ASSUMPTIONS	Fair value of the warrants immediately before the change: SCHEDULE OF FAIR VALUE OF WARRANT USING ASSUMPTIONS Fair value of the warrants A Warrant B Warrant Expected volatility (%) 150.5 % 158.7 % Risk-free interest rate (%) 0.04 % 0.08 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 0.18 1.18 Conversion price 0.26 0.31 Underlying share price (U.S. dollars) 0.07 0.07 Fair value (U.S. dollars in thousands) 3 121 Fair value of the warrants immediately after the change: Fair value of the warrants A Warrant B Warrant Expected volatility (%) 158.7 % 158.7 % Risk-free interest rate (%) 0.08 % 0.22 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 1.18 2.18 Conversion price 0.1 0.1 Underlying share price (U.S. dollars) 0.07 0.07 Fair value (U.S. dollars in thousands) 211 274
SCHEDULE OF FAIR VALUE OF OPTION USING ASSUMPTIONS	SCHEDULE OF FAIR VALUE OF OPTION USING ASSUMPTIONS June 24, 2021 Expected volatility (%) 156.8 % Risk-free interest rate (%) 0.17 % Expected dividend yield 0.0 % Contractual term (years) 1.5 Conversion price - Underlying share price (US dollars) 0.03 Convertible notes amount 397 Fair value of the conversion feature (US dollars in thousands) 117 (*) the conversion price is 85% of the share price, during the period of 5 days preceding the conversion date.
SCHEDULE OF FAIR VALUE OF DEBT	Based on the above, the fair value proportion allocation as of June 24, 2021 was as follows: SCHEDULE OF FAIR VALUE OF DEBT June 24, 2021 (US dollars in thousands) Conversion Component $ 117 Warrants 172 Convertible Notes 61 Total $ 350
Citrine 8LP [Member]
SCHEDULE OF FAIR VALUE OF WARRANT USING ASSUMPTIONS	The assumptions used to perform the calculations are detailed below: SCHEDULE OF FAIR VALUE OF WARRANT USING ASSUMPTIONS A Warrant B Warrant Expected volatility (%) 156.8 % 156.8 % Risk-free interest rate (%) 0.37 % 0.59 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 2.5 3.5 Conversion price 0.1 0.1 Underlying share price (U.S. dollars) 0.03 0.03 Fair value (U.S. dollars in thousands) 184 220

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	SCHEDULE OF STOCK OPTION ACTIVITY Number of Options Weighted Average Exercise Price Outstanding at January 1, 2020 521,065 0.0011 Granted - - Exercised - - Forfeited or expired (474,303 ) 0.0011 Outstanding at December 31, 2020 46,762 0.0011 Granted 23,582,200 0.05 Exercised - - Forfeited or expired - - Outstanding at December 31, 2021 23,628,962 0.05 Number of options exercisable at December 31, 2021 15,672,670 0.05

AGREEMENTS WITH INTELICANNA L_2

AGREEMENTS WITH INTELICANNA LTD (Tables)	12 Months Ended
	Dec. 31, 2021
Agreements With Intelicanna Ltd
SCHEDULE OF FAIR VALUE OF SHARES EXCHANGE AGREEMENT	SCHEDULE OF FAIR VALUE OF SHARES EXCHANGE AGREEMENT Derivative related to Intelicanna’s shares December 31, 2020 Common Stock price 0.83 Expected volatility 57.61 % Conversion price (U.S. dollars) 0.64 Expected term 3.1 Risk free rate 0.09 % Expected dividend yield 0 % Fair value of the derivative (U.S. dollars in thousands) 28 Derivative related to Citrine Global’s shares December 31, 2020 Common Stock price 0.046 Expected volatility 125.19 % Conversion price (U.S. dollars) 0.2 Expected term 3.1 Risk free rate 0.09 % Expected dividend yield 0 % Fair value of the derivative (U.S. dollars in thousands) (100 )

RELATED PARTIES (Tables)

RELATED PARTIES (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
SCHEDULE OF TRANSACTIONS AND BALANCES WITH RELATED PARTIES	SCHEDULE OF TRANSACTIONS AND BALANCES WITH RELATED PARTIES Year ended December 31 2021 2020 U.S. Dollars in thousands Research and development expenses: Fees to officers 48 - Other expenses 26 - 74 - General and administrative expenses: Directors compensation and fees to officers (*) 919 496 (*) Share based compensation 404 - Financing expenses , net: Financial expenses related to convertible loan 1,129 287 Interest on loan (**) - - (**) Less than 1 thousand CITRINE GLOBAL CORP. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS B. Balances with related parties: As of December 31, 2021 2020 U.S. Dollars in thousands Current Assets: Short term loan 15 - Current Liabilities: Convertible notes 1,431 773 Accounts payable 20 312 Accrued compensation 838 -

INCOME TAX (Tables)

INCOME TAX (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
SCHEDULE OF COMPOSITION OF LOSS	SCHEDULE OF COMPOSITION OF LOSS Year ended December 31 2021 2020 U.S. Dollars in thousands U.S. 4,172 8,583 Israel 344 56 Total 4,516 8,639
SCHEDULE OF RECONCILIATION OF EFFECTIVE TAX RATE	SCHEDULE OF RECONCILIATION OF EFFECTIVE TAX RATE 2021 2020 Year ended December 31 2021 2020 U.S. Dollars in thousands Pretax loss 4,516 8,639 Federal tax rate 21 % 21 % Income tax benefit computed at the ordinary tax rate (948 ) (1,814 ) Non-deductible expenses 2 1 Stock-based compensation 96 1,559 Fair value adjustments 246 41 Tax in respect of differences in corporate tax rates (6 ) (1 ) Change in valuation allowance 610 214 Total Income tax - -
SCHEDULE OF DEFERRED TAX ASSETS	SCHEDULE OF DEFERRED TAX ASSETS C 2021 2020 Year ended December 31 2021 2020 U.S. Dollars in thousands Composition of deferred tax assets: Non capital loss carry forwards 908 362 Other timing differences 64 - Valuation allowance (972 ) (362 ) Total deferred tax assets - -
SCHEDULE OF ROLL FORWARD OF VALUATION ALLOWANCE	SCHEDULE OF ROLL FORWARD OF VALUATION ALLOWANCE U.S. Dollars in thousands Balance at January 1, 2020 2,041 Sale of subsidiary (1,893 ) Income tax expense 214 Balance at December 31, 2020 362 Income tax expense 610 Balance at December 31, 2021 972

LOSS PER ORDINARY SHARE (Tables

LOSS PER ORDINARY SHARE (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
SCHEDULE OF BASIC AND DILUTED LOSS PER ORDINARY SHARE	SCHEDULE OF BASIC AND DILUTED LOSS PER ORDINARY SHARE Year ended December 31 2021 2020 Number of shares Weighted average number of shares of Common Stock outstanding attributable to ordinary shareholders 942,568,006 476,622,892 Total weighted average number of shares of Common Stock related to outstanding options, excluded from the calculations of diluted loss per share (*) 15,672,670 46,762 (*) The effect of the inclusion of options and convertible loans in 2021 and 2020 is anti-dilutive.

SUMMARY OF DECONSOLIDATION OF A

SUMMARY OF DECONSOLIDATION OF A SUBSIDIARY (Details) - USD ($) $ in Thousands	Jan. 06, 2020	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 14
Working capital (excluding cash and cash equivalents), net (deficit)	(217)
Long term assets	156
Long term liabilities	(5)
Total value of a subsidiary	(52)
Proceeds from Divestiture of Businesses
Gain from deconsolidation of a subsidiary	$ 52		$ 52

GENERAL (Details Narrative)

GENERAL (Details Narrative) - USD ($) $ in Thousands	Oct. 08, 2021	Sep. 29, 2021	Nov. 22, 2020	Oct. 08, 2020	Aug. 20, 2020	Feb. 23, 2020	Jan. 06, 2020	Dec. 31, 2021	Dec. 31, 2020	Aug. 04, 2020
Property, Plant and Equipment [Line Items]
Debt transferred amount									$ 154
Stockholders' Equity, Reverse Stock Split			On November 22, 2020, certain of the Company’s stockholders representing more than	On October 8, 2020, the Board approved a reverse stock split of the Company’s authorized, issued and outstanding shares of Common Stock, at a ratio between 1-for-40 to 1-for-100, subject to the approval of the Company’s stockholders (the “Reverse Stock Split”). The final ratio of the Reverse Stock Split will be determined by the Board at a later date.
Equity Method Investment, Ownership Percentage			50.00%
Preferred stock shares undesignated			50,000,000
IBO TIsrael Botanicals Ltd [Member]
Property, Plant and Equipment [Line Items]
Subsidiary ownership percentage										60.00%
Debt transferred amount		$ 50
Debt annual interest rate percentage		12.00%
Debt discount capital raised percentage		25.00%
IBO TIsrael Botanicals Ltd [Member] | First Tranche [Member]
Property, Plant and Equipment [Line Items]
Debt transferred amount	$ 15
Traistman Radziejewski Fundacja Ltd. [Member]
Property, Plant and Equipment [Line Items]
Percentage of shares sold							90.00%
Capital stock description							definitive agreements were executed for the sale of 90% of the shares in Novomic Ltd. (“Novomic”) to Traistman Radziejewski Fundacja Ltd. (“TRF”), which was completed on May 14, 2020 (the “Novomic Divestment”), and for the issuance and sale of a number of shares equal after the issuance to 95% of the fully diluted capital stock of the Company to Citrine S A L Group, which was amended on February 23, 2020, to provide for the issuance and sale of the shares in stages (the “Citrine Global Transaction”). Shares of the Company were issued and sold in accordance with this amended agreement to Citrine S A L Group on February 27, 2020, March 5, 2020, and, after the Company amended its Certificate of Incorporation to increase its authorized share capital, on November 11, 2020.
The Cannovation Center [Member]
Property, Plant and Equipment [Line Items]
Percentage of shares hold by certain shareholders					60.00%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Capital stock shares issued			1,550,000,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Capital stock shares issued			1,500,000,000
AR Citrine Agreement [Member]
Property, Plant and Equipment [Line Items]
Percentage of shares sold						95.00%
AR Citrine Agreement [Member] | Second Tranche [Member]
Property, Plant and Equipment [Line Items]
Percentage of shares sold						95.00%
AR Citrine Agreement [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Stock Issued During Period, Shares, New Issues						893,699,276
AR Citrine Agreement [Member] | Maximum [Member] | Initial Tranche [Member]
Property, Plant and Equipment [Line Items]
Stock Issued During Period, Shares, New Issues						452,063,196

SCHEDULE OF RATE OF DEPRECIATIO

SCHEDULE OF RATE OF DEPRECIATION OF PROPERTY PLANT AND EQUIPMENT (Details)	Dec. 31, 2021
Computer Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Rates of depreciation	7.00%
Computer Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Rates of depreciation	33.00%
Land [Member]
Property, Plant and Equipment [Line Items]
Rates of depreciation

SCHEDULE OF FINANCIAL ASSETS AN

SCHEDULE OF FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 1,055	$ 3,105
Total liabilities	$ 2,495	1,702
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		687
Total liabilities		453
Fair Value, Recurring [Member] | Short Term Loan [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		165
Fair Value, Recurring [Member] | Fair Value of Convertible Component in Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities		381
Fair Value, Recurring [Member] | Fair Value of Forward Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities		72
Fair Value, Recurring [Member] | Trading Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		522
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Total liabilities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Short Term Loan [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value of Convertible Component in Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value of Forward Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Trading Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		522
Total liabilities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Short Term Loan [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value of Convertible Component in Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value of Forward Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Trading Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		522
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		165
Total liabilities		453
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Short Term Loan [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		165
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value of Convertible Component in Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities		381
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value of Forward Option [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities		72
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Trading Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets

SCHEDULE OF CHANGES IN FAIR VAL

SCHEDULE OF CHANGES IN FAIR VALUE OF LIABILITIES (Details) - USD ($) $ in Thousands	Aug. 13, 2021	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Classification of embedded conversion feature from liability to equity	$ (670,224)
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Outstanding balance		$ 165
Fair value of issued level 3 assets			145
Interest and change in fair value of short-term loan measured at fair value		(1)	20
Proceeds from repayment of short term loan		(164)
Outstanding balance			165
Outstanding balance		453
Fair value of issued level 3 liability			351
Changes in fair value		115	102
Fair value of convertible component in additional convertible notes issued during the period		116
Classification of embedded conversion feature from liability to equity		(670)
Commitment for issuance of fixed number of ordinary shares		(14)
Outstanding balance			$ 453

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Restricted Cash	$ 10
Debt Securities, Trading		$ 522

INVESTMENT VALUED UNDER THE M_2

INVESTMENT VALUED UNDER THE MEASUREMENT ALTERNATIVE (Details Narrative) - USD ($) $ in Thousands	Jun. 22, 2020	Nov. 22, 2020
Defined Benefit Plan Disclosure [Line Items]
Equity investment percentage		50.00%
Nanomedic Technologies Ltd [Member] | Share Purchase Agreement [Member] | A-1 Preferred Shares [Member]
Defined Benefit Plan Disclosure [Line Items]
Payments for purchase of preferred stock	$ 450
Equity investment percentage	3.30%
Proceeds from issuance of preferred stock	$ 2,200

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 258	$ 6
Less - accumulated depreciation	(2)
Total property and equipment, net	256	6
Computers and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	10	6
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 248

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details Narrative) ₪ in Thousands, $ in Thousands	1 Months Ended		12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2021ILS (₪)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Defined Benefit Plan Disclosure [Line Items]
Depreciation			$ 2	$ 1
The Cannovation Center [Member]
Defined Benefit Plan Disclosure [Line Items]
Payments to Acquire Land	$ 221	₪ 688
[custom:AgreementDescription]	Under the Agreement, Cannovation committed to build and develop the Green Vision Center in accordance with the time frames, terms and conditions of the Agreement. Typically, the initial time frame for completing the development is four (4) years, subject to extensions that the ILA may approve. Upon completion of the development within the time frames and other requirements specified in the Agreement, Cannovation will be entitled, subject to Israeli law, to long term lease agreement (49 years) to the Land (equivalent to ownership rights as most of the land in Israel is government owned and when marketed usually the developers are granted with development/long lease rights).	Under the Agreement, Cannovation committed to build and develop the Green Vision Center in accordance with the time frames, terms and conditions of the Agreement. Typically, the initial time frame for completing the development is four (4) years, subject to extensions that the ILA may approve. Upon completion of the development within the time frames and other requirements specified in the Agreement, Cannovation will be entitled, subject to Israeli law, to long term lease agreement (49 years) to the Land (equivalent to ownership rights as most of the land in Israel is government owned and when marketed usually the developers are granted with development/long lease rights).
Land	$ 27		$ 27

SCHEDULE OF FAIR VALUE OF CONVE

SCHEDULE OF FAIR VALUE OF CONVERTIBLE FEATURE USING VALUATION ASSUMPTIONS (Details) - USD ($) $ / shares in Units, $ in Thousands		Dec. 29, 2021	Aug. 13, 2021	Jun. 24, 2021	Jun. 12, 2020	Dec. 31, 2020	Dec. 31, 2021
Credit Derivatives [Line Items]
Risk-free interest rate (%)		1.29%
Expected dividend yield		0.00%
Contractual term (years)		5 years
Convertible notes amount						$ 773	$ 1,431
Fair value of the conversion feature (U.S. dollars in thousands)		$ 519
Loan One [Member]
Credit Derivatives [Line Items]
Expected volatility (%)			149.04%			164.43%
Risk-free interest rate (%)			0.05%			0.10%
Expected dividend yield			0.00%			0.00%
Contractual term (years)			4 months 2 days	1 year 6 months		11 months 12 days
Conversion price	[1]
Underlying share price (U.S. dollars)			$ 0.05			$ 0.045
Convertible notes amount			$ 1,312			$ 1,275
Fair value of the conversion feature (U.S. dollars in thousands)			$ 379			$ 381
Conversion price percentage					85.00%
Loan Two [Member]
Credit Derivatives [Line Items]
Expected volatility (%)			151.48%	156.80%
Risk-free interest rate (%)			0.13%	0.17%
Expected dividend yield			0.00%	0.00%
Contractual term (years)			1 year 4 months 9 days
Conversion price	[2]
Underlying share price (U.S. dollars)			$ 0.05	$ 0.3
Convertible notes amount			$ 397	$ 397
Fair value of the conversion feature (U.S. dollars in thousands)			$ 115	$ 117
Conversion price percentage					85.00%
Black-Scholes Option-Pricing Model [Member]
Credit Derivatives [Line Items]
Expected volatility (%)					65.69%	164.43%
Risk-free interest rate (%)					0.18%	0.10%
Expected dividend yield					0.00%	0.00%
Contractual term (years)					1 year 6 months	11 months 12 days
Conversion price	[3]
Underlying share price (U.S. dollars)					$ 0.21	$ 0.045
Convertible notes amount					$ 1,275	$ 1,275
Fair value of the conversion feature (U.S. dollars in thousands)					$ 285	$ 381
Conversion price percentage					85.00%	85.00%
[1]	the conversion price is 85
[2]	the conversion price is 85
[3]	the conversion price is 85

SCHEDULE OF FAIR VALUE OF CON_2

SCHEDULE OF FAIR VALUE OF CONVERTIBLE FEATURE USING VALUATION ASSUMPTIONS (Details) (Parenthetical)	Dec. 31, 2020	Jun. 12, 2020
Black-Scholes Option-Pricing Model [Member]
Credit Derivatives [Line Items]
Conversion price percentage	85.00%	85.00%

SUMMARY OF WARRANTS (Details)

SUMMARY OF WARRANTS (Details)	Dec. 31, 2021$ / shares
Measurement Input, Share Price [Member] | Warrants A [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Common Stock price	$ 0.21
Measurement Input, Share Price [Member] | Warrants B [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Common Stock price	$ 0.21
Measurement Input, Price Volatility [Member] | Warrants A [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	65.31
Measurement Input, Price Volatility [Member] | Warrants B [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	68.73
Measurement Input, Expected Term [Member] | Warrants A [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption, warrant contractual term (years)	1 year
Measurement Input, Expected Term [Member] | Warrants B [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption, warrant contractual term (years)	2 years
Measurement Input, Risk Free Interest Rate [Member] | Warrants A [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0.17
Measurement Input, Risk Free Interest Rate [Member] | Warrants B [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0.19
Measurement Input, Expected Dividend Rate [Member] | Warrants A [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0
Measurement Input, Expected Dividend Rate [Member] | Warrants B [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0

SCHEDULE OF FAIR VALUE OF WARRA

SCHEDULE OF FAIR VALUE OF WARRANT USING ASSUMPTIONS (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 29, 2021	Jun. 24, 2021	Dec. 31, 2021
Risk-free interest rate (%)	1.29%
Expected dividend yield	0.00%
Contractual term (years)	5 years
Fair value (U.S. dollars in thousands)	$ 519
A Warrant [Member] | Citrine 8LP [Member]
Expected volatility (%)		156.80%
Risk-free interest rate (%)		0.37%
Expected dividend yield		0.00%
Contractual term (years)		2 years 6 months
Conversion price		$ 0.1
Underlying share price (U.S. dollars)		$ 0.03
Fair value (U.S. dollars in thousands)		$ 184
B Warrant [Member] | Citrine 8LP [Member]
Expected volatility (%)		156.80%
Risk-free interest rate (%)		0.59%
Expected dividend yield		0.00%
Contractual term (years)		3 years 6 months
Conversion price		$ 0.1
Underlying share price (U.S. dollars)		$ 0.03
Fair value (U.S. dollars in thousands)		$ 220
Before the Change [Member] | A Warrant [Member]
Expected volatility (%)			150.50%
Risk-free interest rate (%)			0.04%
Expected dividend yield			0.00%
Contractual term (years)			2 months 4 days
Conversion price			$ 0.26
Underlying share price (U.S. dollars)			$ 0.07
Fair value (U.S. dollars in thousands)			$ 3
Before the Change [Member] | B Warrant [Member]
Expected volatility (%)			158.70%
Risk-free interest rate (%)			0.08%
Expected dividend yield			0.00%
Contractual term (years)			1 year 2 months 4 days
Conversion price			$ 0.31
Underlying share price (U.S. dollars)			$ 0.07
Fair value (U.S. dollars in thousands)			$ 121
After the Change [Member] | A Warrant [Member]
Expected volatility (%)			158.70%
Risk-free interest rate (%)			0.08%
Expected dividend yield			0.00%
Contractual term (years)			1 year 2 months 4 days
Conversion price			$ 0.1
Underlying share price (U.S. dollars)			$ 0.07
Fair value (U.S. dollars in thousands)			$ 211
After the Change [Member] | B Warrant [Member]
Expected volatility (%)			158.70%
Risk-free interest rate (%)			0.22%
Expected dividend yield			0.00%
Contractual term (years)			2 years 2 months 4 days
Conversion price			$ 0.1
Underlying share price (U.S. dollars)			$ 0.07
Fair value (U.S. dollars in thousands)			$ 274

SCHEDULE OF FAIR VALUE OF OPTIO

SCHEDULE OF FAIR VALUE OF OPTION USING ASSUMPTIONS (Details) - USD ($)		Dec. 29, 2021	Jun. 24, 2021
Risk-free interest rate (%)		1.29%
Expected dividend yield		0.00%
Convertible notes amount			$ 350,000
Fair value of the conversion feature (US dollars)			$ 308,000
Citrine 8LP [Member] | Monte Carlo Simulation Model [Member]
Expected volatility (%)			156.80%
Risk-free interest rate (%)			0.17%
Expected dividend yield			0.00%
Debt Securities, Available-for-sale, Term			1 year 6 months
Conversion price	[1]
Underlying share price (US dollars)			0.03
Convertible notes amount			$ 397
Fair value of the conversion feature (US dollars)			$ 117
[1]	the conversion price is 85% of the share price, during the period of 5 days preceding the conversion date.

SCHEDULE OF FAIR VALUE OF DEBT

SCHEDULE OF FAIR VALUE OF DEBT (Details) $ in Thousands	Jun. 24, 2021USD ($)
Short-term Debt [Line Items]
Debt Instrument, Fair Value Disclosure	$ 350
Conversion Component [Member]
Short-term Debt [Line Items]
Debt Instrument, Fair Value Disclosure	117
Warrants [Member]
Short-term Debt [Line Items]
Debt Instrument, Fair Value Disclosure	172
Convertible Notes [Member]
Short-term Debt [Line Items]
Debt Instrument, Fair Value Disclosure	$ 61

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Aug. 13, 2021	Jun. 24, 2021	Apr. 12, 2021	Jun. 12, 2020	Apr. 02, 2020	Dec. 31, 2021	Dec. 31, 2020	Apr. 19, 2020
Short-term Debt [Line Items]
Fair value of warrant issued							$ 301,665
Convertible notes						$ 580
Gain (Loss) on Extinguishment of Debt						(620)
Fair Value Adjustment of Warrants		$ 404
Convertible Debt, Fair Value Disclosures		308
Conversion price	$ 670,224
Short-term Debt						$ 670
Warrants A [Member]
Short-term Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						5,589,172
Warrants B [Member]
Short-term Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						5,589,172
Common Stock [Member]
Short-term Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						11,178,344
CL Agreement [Member]
Short-term Debt [Line Items]
Notes payable				$ 1,000				$ 170
Description on agreement terms				the CL Agreement was amended (hereafter “Amendment”) to provide that for each draw down made by the Company under the CL Agreement, the Buyer shall be entitled to receive two types of warrants: A warrants and B warrants, with the A warrants exercisable at any time between 6 and 12 months after issuance for an exercise price per share equal to 1.25 times the average of the closing prices of the 3 trading days preceding the draw down, and the B warrants exercisable at any time between 6 and 24 months after issuance for an exercise price per share equal to 1.5 times the average of the closing prices of the 5 trading days preceding the draw down, and that the number of each of the A warrants and the B warrants issued will be equal to the draw down amount divided by the average of the closing prices of the 3 trading days preceding the draw down, and that these amended terms will apply in respect of all draw downs, including drawdowns made prior to the date of the amendment.
[custom:ProceedsFromInvestment]			$ 5,000
Gain (Loss) on Extinguishment of Debt			620
Related Party Costs			$ 361
Principal amount	$ 1,520
Debt maturity date	Jul. 31, 2023
Conversion price per share	$ 0.10
Debt Instrument, Description	the holders of the Outstanding CL Notes to honor draw down notice for balance of remainder of the $1,800 thousands originally committed to under the CL Agreement (i.e., $280 thousands) through March 31, 2022.
CL Agreement [Member] | Minimum [Member]
Short-term Debt [Line Items]
Proceeds from investment	$ 5,000
CL Agreement [Member] | Warrants B [Member]
Short-term Debt [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.10
Buyer [Member] | CL Agreement [Member] | Notes [Member]
Short-term Debt [Line Items]
Debt Instrument, Periodic Payment, Principal					$ 1,800
Debt Instrument, Interest Rate, Stated Percentage					6.00%
Common stock conversion price percentage					85.00%
Discount percentage					15.00%
Debt Instrument, Maturity Date, Description					each Note will mature 18 months following the payment date.
Citrine 8LP [Member]
Short-term Debt [Line Items]
Proceeds from Loans		$ 350
Citrine 8LP [Member] | A Warrant [Member]
Short-term Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		10,500,105
Citrine 8LP [Member] | B Warrant [Member]
Short-term Debt [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		10,500,105
Citrine 8LP [Member] | Warrant [Member]
Short-term Debt [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.10
Warrants and Rights Outstanding, Maturity Date		Dec. 24, 2023

SHAREHOLDERS_ EQUITY (Details N

SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

Nov. 22, 2020

Nov. 12, 2020

Nov. 11, 2020

Oct. 08, 2020

Mar. 05, 2020

Feb. 23, 2020

Jan. 29, 2020

Mar. 31, 2020

Feb. 29, 2020

Dec. 31, 2020

Dec. 31, 2021

Dec. 31, 2020

Nov. 08, 2020

Class of Stock [Line Items]

Common stock, par value

$ 0.0001

$ 0.0001

$ 0.0001

Fair value of shares issued

28,222,082

Fair value of service

$ 9,158

Reverse stock split

On November 22, 2020, certain of the Company’s stockholders representing more than

On October 8, 2020, the Board approved a reverse stock split of the Company’s authorized, issued and outstanding shares of Common Stock, at a ratio between 1-for-40 to 1-for-100, subject to the approval of the Company’s stockholders (the “Reverse Stock Split”). The final ratio of the Reverse Stock Split will be determined by the Board at a later date.

Investors [Member]

Class of Stock [Line Items]

Common stock, par value

$ 0.0001

$ 0.0001

Legal Advisor [Member]

Class of Stock [Line Items]

Fair value of shares issued

13,222,082

15,000,000

Fair value of service

$ 4,785

Share-based Payment Arrangement, Expense

$ 1,034

3,751

Chief Financial Officer [Member]

Class of Stock [Line Items]

Fair value of shares issued

1,411,104

1,411,104

Fair value of service

155

AR Citrine Agreement [Member] | Maximum [Member]

Class of Stock [Line Items]

Number of common stock shares issued

893,699,276

Agreement [Member] | Legal Advisor [Member]

Class of Stock [Line Items]

Fair value of service

$ 4,218

Share-based Payment Arrangement, Expense

$ 703

$ 3,515

Common Stock [Member]

Class of Stock [Line Items]

Conversion of Stock, Shares Issued

10,344,828

Number of common stock shares issued

445,702,721

864,997,122,000

Fair value of shares issued

29,633,186,000

Fair value of service

$ 3

Common Stock [Member] | Investors [Member]

Class of Stock [Line Items]

Number of common stock shares issued

432,996,555

432,996,555

Undesignated Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

(50,000,000)

Redeemable Convertible Series A Preferred Stock [Member]

Class of Stock [Line Items]

Conversion of Stock, Shares Converted

10,344,828

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares	Dec. 29, 2021	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Weighted Average Exercise Price, Granted	$ 0.022
Employees and Directors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of Options outstanding, beginning balance		46,762	521,065
Weighted Average Exercise Price outstanding, beginning balance		$ 0.0011	$ 0.0011
Number of Options, Granted		23,582,200
Weighted Average Exercise Price, Granted		$ 0.05
Number of Options, Exercised
Weighted Average Exercise Price, Exercised
Number of Options, Forfeited or expired			(474,303)
Weighted Average Exercise Price, Forfeited or expired			$ 0.0011
Number of Options, outstanding, ending balance		23,628,962	46,762
Weighted Average Exercise Price, ending balance		$ 0.05	$ 0.0011
Options exercisable, ending balance		15,672,670
Weighted Average Exercise Price, Options exercisable, ending balance		$ 0.05

STOCK OPTIONS (Details Narrativ

STOCK OPTIONS (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Dec. 29, 2021	Aug. 15, 2021	Nov. 11, 2020	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option exercise price		$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.29%
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedVolatilityRate]	152.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.022
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 519
Share-based Payment Arrangement, Noncash Expense					$ 456
Remaining expense from stock based compensation					$ 63
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term					6 months
Options outstanding and exercisable, intrinsic value					$ 1
Shares issued for granted to service				28,222,082
David Kretzmer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options purchase		9,425,680
Ilanit Halperin [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options purchase		9,425,680
Doron Birger [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options purchase		2,365,420
Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued for granted to service			1,411,104	1,411,104
2018 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance		90,000,000

SCHEDULE OF FAIR VALUE OF SHARE

SCHEDULE OF FAIR VALUE OF SHARES EXCHANGE AGREEMENT (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)$ / shares
Derivative Related to Intelicanna's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the derivative | $	$ 28
Derivative Related to Citrine Global's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of the derivative | $	$ (100)
Measurement Input, Share Price [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Common stock price, shares | $ / shares	$ 0.83
Measurement Input, Share Price [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Common stock price, shares | $ / shares	$ 0.046
Measurement Input, Price Volatility [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of shares, measurement input, percentage	57.61
Measurement Input, Price Volatility [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of shares, measurement input, percentage	125.19
Conversion Price (U.S. Dollars) [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of shares, measurement input, percentage	0.64
Measurement Input, Expected Term [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption, shares contractual term (years)	3 months 3 days
Measurement Input, Expected Term [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption, shares contractual term (years)	3 months 3 days
Measurement Input, Risk Free Interest Rate [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of shares, measurement input, percentage	0.09
Measurement Input, Risk Free Interest Rate [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of shares, measurement input, percentage	0.09
Measurement Input, Expected Dividend Rate [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of shares, measurement input, percentage	0
Measurement Input, Expected Dividend Rate [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of shares, measurement input, percentage	0
Measurement Input, Conversion Price [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of shares, measurement input, percentage	0.2

AGREEMENTS WITH INTELICANNA L_3

AGREEMENTS WITH INTELICANNA LTD (Details Narrative) $ in Thousands	Aug. 09, 2021USD ($)shares	Nov. 12, 2020shares	Sep. 17, 2020USD ($)shares	Jul. 09, 2020USD ($)	Jul. 09, 2020ILS (₪)	Jun. 25, 2020USD ($)	Jun. 25, 2020ILS (₪)	May 31, 2020	Dec. 31, 2021USD ($)	Dec. 31, 2021ILS (₪)	Dec. 31, 2020USD ($)shares
Stock Issued During Period, Value, New Issues | $											$ 177
Gross Profit | $											$ (2)
Intelicanna Ltd. [Member]
Debt instrument started percentage									12.00%	12.00%
Repaid loan amount									$ 14	₪ 46,000
Common Stock [Member]
Number of ordinary shares exchanged											2,143,470,000
Stock Issued During Period, Shares, New Issues		445,702,721									864,997,122,000
Stock Issued During Period, Value, New Issues | $											$ 86
Agreement [Member] | Intelicanna Ltd. [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value						$ 290	₪ 1,000,000
Debt instrument started percentage						6.00%	6.00%
Agreements [Member] | Intelicanna Ltd. [Member]
Gross Profit						$ 600	₪ 2,000,000
Intelicanna Ltd. [Member]
Number of ordinary shares exchanged			2,143,470
Fair value of change in traded securities | $			$ 50
Sale of Stock, Number of Shares Issued in Transaction	619,589
[custom:AggregateGrossproceedsOfOrdinaryShares]	1,261,000
Sale of Stock, Consideration Received on Transaction | $	$ 389
Intelicanna Ltd. [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues			619,589
Intelicanna Ltd. [Member] | Share Exchange Agreement [Member]
Description on agreement terms								The Share Exchange Agreement provides that (i) the number of shares each party issues to the other will be calculated by dividing $500 thousand by the volume weighted average price (VWAP) of the issuing party’s shares in the three trading days preceding the signing of the agreement, (ii) the issuance by Intelicanna will take place upon, and subject to, receipt of approval from the Tel Aviv Stock Exchange, and the issuance by the Company will follow immediately thereafter, and (iii) the parties may not sell the shares within the first six months after issuance, and thereafter the parties may sell the shares issued to them if the shares become registered through a prospectus approved by the relevant securities authority, or under an exemption provided by applicable securities law, subject to a limit on the number of shares either party may sell per day. The Agreement for future Issuance of Shares provides that a fall in a share price of a party, not exceeding 20%, measured six months after issuance of shares by both parties pursuant the Share Exchange Agreement, will be offset by the issuance of additional shares to the other party to bring up to $500 thousand the total value of the shares issued to the other party. On August 15, 2021, the Company’s board of directors determined that it is required to issue to Intelicanna 619,589 shares of the Company’s common stock and has authorized the issuance of such shares to Intelicanna. As of December 31, 2021, the common stock have not been issued yet. As such, the Company recorded an additional $14 thousands to be issued to Intellicanna.
Intelicanna Ltd. [Member] | Services Agreement [Member]
Description on agreement terms						the Company and the Israeli Subsidiary entered into an agreement to grant Intelicanna Ltd. (“Intelicanna”) New Israeli Shekel (“NIS”) 1 million in cash (approximately $290 thousand) in direct financing for working capital purposes. The financing will bear 6% annual interest, and Intelicanna will make additional payments equal to 6% of its gross revenues from the date the financing was received and until the date Intelicanna’s aggregate gross revenues reach NIS 2 million (approximately $600 thousand).If the total of the 6% interest plus the additional payments would result in a return of less than 12% per year to the Company, the interest would be increased to bring the total return to 12%. Every three months Intelicanna must pay the interest, and after 12 months, it must repay the capital, plus the total of the additional payments due, plus any outstanding interest, and it must pay interest of 2% per month on any late payments, provided, however, that until the foregoing obligations are paid in full, Intelicanna must pay 50% of its gross revenues to the Company upon receipt. If Intelicanna does not pay all amounts due within 18 months, it shall, at the Company’s option, issue to the Company a number of its shares equal to NIS 1.5 million (approximately $0.45 million) divided by the lower of (i) volume weighted average price (VWAP) of the three trading days prior to the lapse of the 18 months, and (ii) VWAP of the three trading days prior to the signing of the financing agreement.	the Company and the Israeli Subsidiary entered into an agreement to grant Intelicanna Ltd. (“Intelicanna”) New Israeli Shekel (“NIS”) 1 million in cash (approximately $290 thousand) in direct financing for working capital purposes. The financing will bear 6% annual interest, and Intelicanna will make additional payments equal to 6% of its gross revenues from the date the financing was received and until the date Intelicanna’s aggregate gross revenues reach NIS 2 million (approximately $600 thousand).If the total of the 6% interest plus the additional payments would result in a return of less than 12% per year to the Company, the interest would be increased to bring the total return to 12%. Every three months Intelicanna must pay the interest, and after 12 months, it must repay the capital, plus the total of the additional payments due, plus any outstanding interest, and it must pay interest of 2% per month on any late payments, provided, however, that until the foregoing obligations are paid in full, Intelicanna must pay 50% of its gross revenues to the Company upon receipt. If Intelicanna does not pay all amounts due within 18 months, it shall, at the Company’s option, issue to the Company a number of its shares equal to NIS 1.5 million (approximately $0.45 million) divided by the lower of (i) volume weighted average price (VWAP) of the three trading days prior to the lapse of the 18 months, and (ii) VWAP of the three trading days prior to the signing of the financing agreement.
Repaid loan amount				$ 145	₪ 500,000	$ 450	₪ 1,500,000
Citrine Global Israel Ltd. [Member] | Services Agreement [Member]
Description on agreement terms						the Israeli Subsidiary entered into a services agreement with Intelicanna to provide business development and consulting services to Intelicanna, including assistance with raising financing (the “Services Agreement”) (references in this paragraph to the Company include the Israeli Subsidiary). The terms of the Services Agreement include: (1) the Company will, for a period of 18 months, assist Intelicanna to raise up to NIS 15 million for Intelicanna’s working capital purposes, whether through issuance of convertible securities or any other means; all sums raised must be approved in advance by the Company, and in accordance with a business plan presented to the Company from time to time; the Company will have no obligation under the Services Agreement to invest in Intelicanna, and no liability if its efforts to source financing for Intelicanna are unsuccessful; (2) in the event Intelicanna raises funds through assistance from the Company, the Company will be entitled to (i) cash consideration equal to 5% of any amount raised, whether directly from the Company, or from any of its affiliates or any unrelated third party, and (ii) options to acquire a number of shares of Intelicanna equal to 5% of the amount raised divided by the Exercise Price; the “Exercise Price” will be the price per share at which the amount was raised, or if it was not raised through issuance of shares, the price per share at which Intelicanna last raised funds through issuance of shares; and (3) for one or more periods of at least 90 days, each time at Intelicanna’s request which the Company may accept or decline at its discretion, the Company will provide business development and strategy-building services, including: consulting on strategy and business plan; assistance defining financing needs; helping identify ways to develop potential sources of finance; and ongoing consulting support to Intelicanna’s management team and board. Intelicanna will pay the Company a fee of NIS 2,500 per day for such services.	the Israeli Subsidiary entered into a services agreement with Intelicanna to provide business development and consulting services to Intelicanna, including assistance with raising financing (the “Services Agreement”) (references in this paragraph to the Company include the Israeli Subsidiary). The terms of the Services Agreement include: (1) the Company will, for a period of 18 months, assist Intelicanna to raise up to NIS 15 million for Intelicanna’s working capital purposes, whether through issuance of convertible securities or any other means; all sums raised must be approved in advance by the Company, and in accordance with a business plan presented to the Company from time to time; the Company will have no obligation under the Services Agreement to invest in Intelicanna, and no liability if its efforts to source financing for Intelicanna are unsuccessful; (2) in the event Intelicanna raises funds through assistance from the Company, the Company will be entitled to (i) cash consideration equal to 5% of any amount raised, whether directly from the Company, or from any of its affiliates or any unrelated third party, and (ii) options to acquire a number of shares of Intelicanna equal to 5% of the amount raised divided by the Exercise Price; the “Exercise Price” will be the price per share at which the amount was raised, or if it was not raised through issuance of shares, the price per share at which Intelicanna last raised funds through issuance of shares; and (3) for one or more periods of at least 90 days, each time at Intelicanna’s request which the Company may accept or decline at its discretion, the Company will provide business development and strategy-building services, including: consulting on strategy and business plan; assistance defining financing needs; helping identify ways to develop potential sources of finance; and ongoing consulting support to Intelicanna’s management team and board. Intelicanna will pay the Company a fee of NIS 2,500 per day for such services.
Stock Issued During Period, Value, New Issues | ₪							₪ 15,000,000
Fee for service rendered | ₪							₪ 2,500

SCHEDULE OF TRANSACTIONS AND BA

SCHEDULE OF TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Share base compensation		$ 456
Research and development expense		96	17
Short term loan		15
Convertible notes		1,431	773
Accounts payable		20	312
Accrued compensation		838
Related Party [Member]
Related Party Transaction [Line Items]
Research and development expense		74
Interest on loan	[1]
Research and Development Expense [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Fees to officers		48
Other expenses		26
General and Administrative Expense [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Share base compensation		404
Directors compensation and fees to officers		$ 919	$ 496
[1]	Less

RELATED PARTIES (Details Narrat

RELATED PARTIES (Details Narrative) - USD ($)	Sep. 29, 2021	Aug. 15, 2021	Feb. 28, 2020	Dec. 31, 2021	Dec. 31, 2020	Aug. 09, 2021	Mar. 31, 2021	Nov. 22, 2020	May 31, 2020	Feb. 29, 2020
Related Party Transaction [Line Items]
Advances to a reated party									$ 4,000
[custom:AwardBonusPercentageDescription]		the board determined to award a bonus to the Company’s Chairperson of the Board, CEO, CFO, officers, directors and senior management equal to two percent (2%) of any capital raise, subject to prior repayment of the outstanding convertible loans and so long as the payment thereof would be from available funds and part of the Company’s operating budget for a minimum period of 18 months. In addition, the Board agreed to a bonus Company’s Chairperson of the Board, CEO, CFO, officers, directors and senior management of 2% from operating profits which will become payable upon the fulfillment of certain specified targets that the Board will establish, subject to prior repayment of the outstanding convertible loans and so long as the payment thereof would be from available funds and as part of the Company’s operating budget for a minimum period of 18 months.
Equity investment percentage								50.00%
IBO TIsrael Botanicals Ltd [Member]
Related Party Transaction [Line Items]
Equity investment percentage						60.00%
Ilan BenIshay [Member]
Related Party Transaction [Line Items]
Investment			$ 1,800,000
Related party fee		$ 2	$ 4
IBOT [Member]
Related Party Transaction [Line Items]
Advances to a reated party	$ 50,000
Debt Instrument, Maturity Date, Description	12 month maturity date
Debt Instrument, Interest Rate During Period	12.00%
Debt Instrument, Interest Rate, Effective Percentage	25.00%
Elharar Soffer [Member]
Related Party Transaction [Line Items]
Advances to a reated party										$ 20,000
[custom:AwardBonusPercentageDescription]		the board of directors of Cannovation determined to adjust the compensation of the Chairperson (and interim Chief Executive Officer), Ora Elharar Soffer, to $10 thousands per month, in each case retroactive to July 1, 2021. These amounts would be paid at such time as Cannovation shall become due and payable from, and such time as Cannovation shall have, available funds therefor and as part of the operating budget for a minimum period of 18 months.
Ora Elharar Soffer [Member]
Related Party Transaction [Line Items]
Investment										$ 1,800,000
Ms Elharar Soffer [Member]
Related Party Transaction [Line Items]
Compensation earned				$ 499,000	$ 210,000
Mr BenIshay [Member]
Related Party Transaction [Line Items]
[custom:CompensationEarned-0]				86	34
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Advances to a reated party		$ 4,000
Ms Halperin [Member]
Related Party Transaction [Line Items]
[custom:CompensationEarned-0]				$ 171,000	$ 66,000
David Kretzmer [Member]
Related Party Transaction [Line Items]
Advances to a reated party							$ 7,000
[custom:CompensationDescription]		the board of directors of Cannovation determined to adjust the compensation of David Kretzmer, a director at Cannovation, to $2 thousands per month, in each case retroactive to July 1, 2021. These amounts would be paid at such time as Cannovation shall become due and payable from, and such time as Cannovation shall have, available funds therefor and as part of the operating budget for a minimum period of 18 months.

SCHEDULE OF COMPOSITION OF LOSS

SCHEDULE OF COMPOSITION OF LOSS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Total	$ 4,516	$ 8,639
UNITED STATES
Total	4,172	8,583
ISRAEL
Total	$ 344	$ 56

SCHEDULE OF RECONCILIATION OF E

SCHEDULE OF RECONCILIATION OF EFFECTIVE TAX RATE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Pretax loss	$ 4,516	$ 8,639
Federal tax rate	21.00%	21.00%
Income tax benefit computed at the ordinary tax rate	$ (948)	$ (1,814)
Non-deductible expenses	2	1
Stock-based compensation	96	1,559
Fair value adjustments	246	41
Tax in respect of differences in corporate tax rates	(6)	(1)
Change in valuation allowance	610	214
Total Income tax

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Non capital loss carry forwards	$ 908	$ 362
Other timing differences	64
Valuation allowance	(972)	(362)	$ (2,041)
Total deferred tax assets

SCHEDULE OF ROLL FORWARD OF VAL

SCHEDULE OF ROLL FORWARD OF VALUATION ALLOWANCE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Balance	$ 362	$ 2,041
Sale of subsidiary		(1,893)
Income tax expense	610	214
Balance	$ 972	$ 362

INCOME TAX (Details Narrative)

INCOME TAX (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 3,954	$ 337
Corporate Tax Rate [Member]
Operating Loss Carryforwards [Line Items]
Corporate tax rate	23.00%
Statutory Rate [Member]
Operating Loss Carryforwards [Line Items]
Corporate tax rate	21.00%

SCHEDULE OF BASIC AND DILUTED L

SCHEDULE OF BASIC AND DILUTED LOSS PER ORDINARY SHARE (Details) - shares		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Weighted average number of shares of Common Stock outstanding attributable to ordinary shareholders		942,568,006	476,622,892
Total weighted average number of shares of Common Stock related to outstanding options, excluded from the calculations of diluted loss per share	[1]	15,672,670	46,762
[1]	The effect of the inclusion of options and convertible loans in 2021 and 2020 is anti-dilutive.

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] $ / shares in Units, $ in Thousands	Mar. 30, 2022	Jan. 05, 2022USD ($)$ / sharesshares	Feb. 08, 2022ft²
Subsequent Event [Line Items]
Proceeds from Loans | $		$ 180
Proceeds from Contributed Capital | $		$ 5,000
Debt Instrument, Interest Rate, Stated Percentage		9.00%
Area of Land | ft²			11,687
Bonus description	the Company Board determined to allot the Bonus referred to in Note 9G as follows: 65% of such bonus amounts were allocated to the Company’s Chief Executive Officer, 25% to the Company’s Chief Financial Officer and 5% to one of the directors
Convertible Note Agreement [Member]
Subsequent Event [Line Items]
Warrant exercise price		$ 0.05
Conversion price per share		$ 0.05
Series A Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Outstanding | shares		6,666,667
Series B Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Outstanding | shares		6,666,667
Warrant exercise price		$ 0.05